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1. INTRODUCTION 
The plaque-induced forms of periodontal diseases are the most prevalent chronic 
inflammatory conditions seen in humans worldwide, affecting nearly half of the adult 
population. Periodontitis is a major health problem reducing the quality of life and causing tooth 
loss, disability, masticatory dysfunction, poor nutritional status and compromised speech. 
Periodontitis is also independently associated with systemic chronic inflammatory diseases 
including atherogenic cardiovascular disease, type 2 diabetes mellitus, rheumatoid arthritis, 
chronic kidney disease, obesity and chronic obstructive pulmonary disease [1–3]. 
Possible therapeutic methodologies include scaling and root planing and surgical 
intervention, all of which are supplemented by the administration of systemic antibiotics and 
local chlorhexidine-containing mouthwashes. By scaling and root planing, the debridement of 
deep pockets is often difficult, while recovery after surgical intervention is long. Using adjuvant 
systemic antibiotics burdens the patient as adverse events may be observed; and this does not 
provide a suitable concentration of the active agent in the periodontal pockets. Moreover, the 
administration of adjuvant antibiotics may contribute to the emergence of resistant bacterial 
strains [4–9]. 
In the last 10—15 years, local drug delivery systems received considerable attention. 
Numerous publications focused on local delivery systems containing antimicrobial drugs. It 
was established that the application of local drug delivery systems alone or in combination with 
other dental procedures may result in a more efficient treatment compared to the systemic 
administration of antimicrobial drugs [4,5,8–11]. Therefore, local delivery systems with 
incorporated antibiotics is a promising approach to treating periodontitis. Subgingival 
administration of these systems is most prevalent in aiming at the increased bioavailability of 
drug formulations. Compared to systemic drug delivery, 100-fold larger concentrations of the 
antimicrobial agents can be achieved at subgingival sites. Locally administrable formulations 
may provide prolonged liberation of antimicrobial agents and protection from decomposition 
in hydrophilic media. These systems may also mask the unpleasant taste of drugs, and may 
prevent the emergence of antimicrobial resistance, and the appearance of side effects of oral 
antibiotic use. 
Considering the expected properties of formulations, there is a great need for the 
development of topically used ideal carrier systems, which would allow a wider, safer and more 
promising application of active ingredients. 
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2. LITERATURE BACKGROUND 
2.1. Periodontal disease 
Periodontitis is predominantly a bacterial infection involving the accumulation of different 
bacteria on the non-shedding surfaces of the oral cavity. In susceptible patients, dental plaque 
comprises periodontal pathogenic microorganisms that initiate and trigger a dysfunctional 
inflammatory immune response which destroys the supporting tissues. Microbial dysbiosis is a 
necessary, but alone insufficient condition for the development of periodontal destruction. The 
host response to the initiating periodontopathogens is predominantly a genetically determined 
non-modifiable risk factor. Most of the systemic factors are candidates for modification or 
elimination, which plays a role in changing the susceptibility or resistance of individuals to the 
treatment. Such modifiable factors are smoking, poorly controlled diabetes mellitus, obesity, 
stress, osteopenia and inadequate intake of calcium and Vitamin D [1]. The most important 
modifiable local risk factor is poor oral hygiene, which may initiate the infective inflammatory 
process in periodontal tissues. 
2.1.1. Anatomy of the periodontium 
The periodontium is a complex structure composed of the gingiva, periodontal ligament 
(PDL), cementum and alveolar bone. The primary functions of the periodontium are to attach 
the tooth to the bone and to protect the underlying structures from the oral microflora. The 
epithelium of the gingiva is composed of stratified squamous epithelium, which is primarily 
orthokeratinized or parakeratinized [12]. The gingiva covers the supracrestal surface of the root 
and the alveolar bone and includes epithelial and connective tissue. The transition from gingival 
to sulcular and junctional epithelium is near the tooth surface. The gingival sulcus is a shallow 
opening that is bound apically by the coronal aspect of the junctional epithelium, laterally by 
the sulcular epithelium, and medially by tooth surface, and superiorly exits into the oral cavity. 
The junctional epithelium is supported by the supracrestal connective tissue fibers of the 
gingiva. These structures create an initial barrier between the bacterial plaque and the 
subepithelial components of the periodontium. Apically, the PDL (connective tissue 
attachment) connects the root cementum to the alveolar bone, functionally supporting the tooth 
within the mandible or maxilla. The portions of the PDL fibers that are embedded in cementum 
and alveolar bone are called Sharpey’s fibers. In addition to providing tooth support, the unique 
design of the periodontium allows for the distribution of the forces of mastication [13]. 
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2.1.2. Etiology of periodontal disease 
Inflammation of the gingiva (or gingivitis), is the most common form of gingival disease. 
This is a result of the presence of local irritants, such as the toxins of the microorganisms related 
to dental plaque and calculus. The inflammation can result in ulcerative, necrotic and 
proliferative changes in the gingival tissues. The gingival sulcus can deepen, which may cause 
harm to the supporting periodontal tissues. Injury of these supporting tissues may become 
irreversible. Persistence of inflammation can result in hyperplastic changes of the gingival 
tissues and extension of the crest of the gingival margin toward the crown [14]. The normal 
protective behavior of the sulcus and the junctional epithelium becomes dysfunctional as 
inflammation causes a change in the quality of these structures and tissue proliferation. A 
pocket is formed from the sulcus; therefore, microorganisms and their toxins can access the 
exposed subgingival tissues which undergo further pathologic changes. The persistence of this 
process may result in the separation of the epithelial junction from the root and further 
enlargement of the pocket. The extension of inflammation from the margin of the gingiva into 
the supporting periodontal tissues marks the transition from gingivitis to periodontitis. The 
essential problem of periodontal disease is the destruction of the alveolar bone with a loss of 
crestal height and PDL destruction. Untreated periodontal disease may lead to the loosening of 
the teeth and eventually tooth loss [12,13]. 
 
Figure 1. Progression of periodontal disease. A: healthy gingiva; B: gingivitis; C: periodontitis [12]. 
2.2. Treatment methodologies for periodontal disease 
Treatment of periodontitis involves a fine balance of various non-surgical and surgical 
methods carried out in order to reduce periodontal pocket depth, access residual plaque, initiate 
the regeneration of periodontal supporting tissues and decrease the risk of disease progression. 
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Subgingival anti-infective therapy performed together with self-performed plaque control 
provides significant benefits in clinical parameters and improvement of systemic inflammatory 
markers [15]. 
2.2.1. Nonsurgical and surgical periodontal therapies 
Non-surgical periodontal treatment consists of professional removal of plaque and calculus, 
elimination of plaque retentive factors, oral hygiene instruction, chemical plaque control and 
antibiotic medication. Treatment of teeth with tooth/site-dependent factors is less predictable 
and bears an elevated risk of the progression of  periodontal tissue breakdown [16]. Mechanical 
therapy alone may have limited effect on some periodontopathogens and fail to eliminate them 
in ecological niches [15]. 
 
Figure 2. Mechanical debridement of subgingival tooth surfaces [17]. 
When pocket depth reaches 5 mm, mechanical debridement may not provide sufficient 
removal of subgingival plaque; therefore, surgical therapy may be required. The primary 
purpose of surgical periodontal therapies is to access residual plaque of deep pockets and to 
establish a gingival morphology conducible to efficient plaque control. The outcome of 
periodontal surgery depends on many factors. However, clinical trials show evidence that 
unless patients maintain rigorous postoperative plaque control, the deepening of periodontal 
pockets continues. Moreover, costs of these treatment methods are higher and longer recovery 
periods are needed [15,18,19]. 
2.2.2. Systemic pharmacotherapy 
Systemic antimicrobials are applied adjunctively to mechanical non-surgical and surgical 
treatment and may provide additional benefits in case of very deep pockets or specific microbial 
infections. Systemic antimicrobial therapy is the most effective when the mechanical disruption 
of the subgingival biofilm is performed during subgingival debridement [15,20]. 
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Literature data suggest that a high number of different antimicrobial agents may be effective 
in the adjunctive treatment of periodontal disease, but selection of the proper one may be 
dependent on different factors such as patient age, drug allergy, pregnancy, local factors, drug 
factors and organism related considerations [21]. That is why there is a pool of antibiotics from 
which the dental expert can choose after individual features have been considered. In Table 1, 
a summary of these active agents, their average doses and duration of treatment are shown. 
Table 1. Antibiotics, their dose, frequency of dosage and duration of therapy in the systemic antimicrobial therapy of 
periodontal disease. 
 Dose Frequency Duration 
Amoxicillin 250—1000 mg 
twice, three times 
daily 
7—14 days 
Azithromycin 500 mg once daily 3 days 
Ciprofloxacin 500 mg twice daily - 
Clarithromycin 500 mg twice daily 3 days 
Doxycycline 100 mg once daily 9—14 days 
Metronidazole 200—500 mg 
twice, three times 
daily 
7—14 days 
Tetracycline 250 mg four times daily 21 days 
Administration of antibiotics may be advantageous if they supplement scaling and root 
planing therapies, but overall analysis of the clinical trials conducted indicate that a certain 
combination of two aforementioned agents may provide higher effectiveness [22]. The protocol 
for the combination of AMX and MZ was proposed by Winkelhoff and colleagues. Their results 
showed promising effectiveness when this combination was used [23]. 
In conjunction with the administration of systemic antibiotics, adverse events and antibiotic 
resistance must be taken into consideration. Most common side effects include headache, 
malaise, gastrointestinal discomfort, nausea, vomiting and diarrhea. In addition, other disorders 
affecting the respiratory tract, the skin or the musculoskeletal system may arise. However, these 
side effects, similarly to the ones listed before, were not reported in the case of local drug 
delivery systems containing antimicrobial agents due to the local administration and lower 
concentration of these APIs referring to the entire body [22,24]. 
Antibacterial resistance is an emerging issue which is due to the careless use of antibiotics 
[25]. Not following the therapeutic protocol during systemic antibiotic administration may 
eventuate the emergence of resistant bacteria which can cause treatment failure and tooth loss 
[21,24]. 
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2.2.3. Local pharmacotherapy 
The local delivery of antimicrobial drugs may reduce the systemic adverse effects and 
provide effective drug concentrations in the periodontal pockets to eliminate the pathogens 
from the subgingival area [5,26]. Local application of antibiotics has been advocated for 
patients with localized lesions or a limited amount of non-responding or recurrent sites [15]. In 
the literature, many articles are about the development of various types of delivery systems 
(fibers, films, gels, strips, injectable systems, microparticles) containing different active agents 
(tetracycline, doxycycline, chlorhexidine, clindamycin, metronidazole, amoxicillin, povidone-
iodine) [5,8,34–38,9,27–33]. The possible classification of local drug delivery systems is shown 
in Figure 3. 
 
Figure 3. Possible classification of local drug delivery systems used in periodontitis treatment [39]. 
2.2.3.1. Local drug delivery systems in periodontal therapy 
Advantages of local drug delivery systems over systemic antimicrobials are the following: 
non-invasive and direct administration to the periodontal pockets (site of infection), no first 
pass metabolism, reduced dose and frequency of drug administration and better patient 
compliance. Furthermore, agents unsuitable for systemic therapy can be incorporated into them 
[40]. The features of the ideal local drug delivery system include easy administration, controlled 
drug release, constant drug concentration for a prolonged period in the periodontal pockets, 
biodegradability and biocompatibility [41]. 
Local drug delivery systems
Professionally delivered
Sustained
Film, gels, fibers, 
strips, microspheres, 
liposomes
Non-sustained
Supra- and sub-
gingival irrigators 
(povidone iodine, 
chlorhexidine)
Personally applied
Non-sustained
Oral irrigators 
(chlorhexidine)
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2.2.3.1.1. Strips and films 
Strips and films are polymer-based matrix systems. They are designed to provide controlled 
and sustained delivery of the active agents when placed in the periodontal pocket [4]. Different 
polymers can be used to create these systems. These polymers can be either biodegradable or 
non-biodegradable [42,43]. Ideal thickness of strips and films is between 5 and 200 μm. 
The drug release from strips and films depends on the biodegradability of the polymer. If the 
polymer is biodegradable, the drug is released either by diffusion and/or matrix dissolution or 
erosion. In the case of non-biodegradable polymer matrices, drug release is driven only by 
matrix diffusion [43].  
One of the main advantage of strips and films is easily manipulation of shape and size to 
match pocket dimensions. This feature allows easy insertion and lack of discomfort [44]. 
Several studies in literature have used the combination of these polymers to deliver 
antimicrobials such as doxycycline, tetracycline, metronidazole and chlorhexidine. These 
systems were proven to be effective in reducing the clinical variables of periodontal disease 
[41]. 
2.2.3.1.2. Fibers 
Polymers used for creating fibers are either natural (gelatin, chitosan and zein) or synthetic 
(poly(lactide-co-glycolic acid) and polycaprolactone), both can be biodegradable or non-
biodegradable [41]. 
Drugs are loaded into the fibers by passive and active methods, and the efficacy of the drug 
loading depends on the properties of the active agent and polymer, and on the formulation 
method [45,46]. 
After the introduction of fibers into the periodontal pocket, drug release is primarily driven 
by diffusion, swelling and degradation. All of these are dependent on the polymer type and its 
properties like hydrophobicity, hydrophilicity, molecular weight, crystallinity, melting point, 
etc. Drug release of delivery systems also influenced by the features of the incorporated drug 
[47,48]. 
Fibers are highly researched in the field of periodontics, and some of them provided 
improvement for the patients; therefore, they may be advantageous in the treatment of 
periodontal disease [39]. 
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2.2.3.1.3. In situ forming gels as delivery systems 
In situ forming delivery systems offer an interesting potential for the treatment of 
periodontitis. [49,50]. Special needles and syringes are used to introduce these systems into the 
periodontal pocket as liquids. After administration, the injected liquid solidifies or become 
cross-linked and provides sustained or controlled release of the incorporated API. Advantages 
include easy administration, adapted form to the geometry and size of the periodontal pocket 
and easy access to areas that are difficult to reach [51]. 
Gels are often used in the treatment of different oral diseases such as oral ulcers, denture 
stomatitis and desquamative gingival lesions. These applications are possible due to features 
like easy formulation, controlled release, minimum dose frequency and low drug toxicity 
[52,53]. 
Different stimuli (pH, temperature, ions or magnetic force) can induce the cross-linking of 
gels in the periodontal pocket or special mixing needles can be used during the administration. 
Mixing needles are special two-compartment devices in which one compartment contains the 
polymer solution, while the other contains the cross-linking agent. During injection, a special 
needle is used to mix the content of the two compartments before the mixture is delivered into 
the periodontal pocket [39]. 
Various polymers (such as Carbopol, xanthan, carboxy methyl cellulose and chitosan 
[43,54]) can be used to formulate different gels for drug delivery purposes. They can be loaded 
with a wide range of active agents such as antimicrobials [55], bisphosphonates (alendronates 
[56], zoledronates [57]), anti-inflammatory drugs and statins [58]. Literature data indicates that 
local delivery of drug-containing gels has a potential in improving the clinical parameters 
associated with periodontitis. 
In situ forming lyotropic liquid crystalline systems have been also described in the literature 
for periodontal disease treatment [59]. Lyotropic liquid crystalline systems are formed from 
water, surfactants, co-surfactants and oils. There is a definite concentration ratio and 
temperature range in which these systems are formed. An injectable mixture of oils and 
surfactants can be prepared, which will become a lyotropic liquid crystalline system in the 
periodontal pockets, when the mixture comes into contact with water or aqueous media. 
Increased viscosity of systems may lead to longer subgingival retention and sustained release 
of active agent [59,60]. 
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2.2.3.1.4. Microparticulate systems 
Microparticles are spherical polymeric structures in the diameter range of 1–1000 μm. 
Different biodegradable and non-biodegradable polymers can be used to create microspheres. 
Water-soluble (e.g., gelatin, starch) and water-insoluble polymers (such as ethyl cellulose, 
polyethylene) are also used for microencapsulation [61–64]. The polymeric matrix protects the 
active agent from incompatibilities and the effects of the environment, masks the unpleasant 
taste of drugs, enhances bioavailability and provides controlled release [61]. These particles 
can be incorporated into different systems like gels, pastes or chips to deliver to the periodontal 
pocket [64]. 
Results of clinical studies indicate that they may provide adequate concentrations of 
antimicrobial drugs in the periodontal pockets and contribute to the treatment of the disease 
[65–69]. 
2.2.3.1.5. Nanoparticulate systems 
Nanoparticles (dimension less ≤100 nm) have gained considerable attention due to their 
ability to precisely deliver drugs to a target site [70,71]. Drug-loaded nanoparticles are delivered 
to the site of action directly and can provide sustained and controlled release of APIs. Bone 
regenerative and antibiotic activity of these delivery systems are important in the treatment of 
periodontal disease; thus, metallic nanoparticles (copper, silver and titanium dioxide) are under 
thorough investigation [72–76]. 
Nanoparticulate systems also include liposomes, polymeric nanoparticles, polymeric 
micelles and solid lipid nanoparticles [72]. Advantages of these systems include better transport 
through cell membranes, improved drug loading capacity and biocompatibility [77]. 
2.2.3.2. Marketed local drug delivery systems 
2.2.3.2.1. Atridox® 
Atridox® is a subgingival controlled-release delivery system. It composes of a two-syringe 
mixing system. One of the syringes contains 450 mg of the Atrigel® Delivery System, which 
is a bioabsorbable polymeric formulation composed of 36.7% polylactic acid dissolved in 
63.3% N-methyl-2-pyrrolidone (NMP). The other syringe contains 50 mg of doxycycline 
hyclate (hydrochloride hemiethanolate hemihydrate) which is equivalent to 42.5 mg 
doxycycline. After mixing, the product is a yellow viscous liquid which contains 10% of 
doxycycline hyclate. When the mixture comes into contact with the cervicular fluid, the liquid 
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product solidifies. The solidified mixture allows the controlled release of doxycycline hyclate 
for 7 days [78]. 
2.2.3.2.2. Actisite® 
Actisite® is a fiber which can be introduced into the periodontal pocket. The delivery system 
consists of a 23 cm monofilament of ethylene-vinyl acetate copolymer. This device has a 
diameter of 0.5 mm and 12.7 mg of tetracycline hydrochloride dispersed in it. The fiber 
provides continuous release of tetracycline for 10 days. Unfortunately, the marketing of the 
device has been discontinued [79,80]. 
2.2.3.2.3. PerioChip® 
PerioChip® (chlorhexidine gluconate) is a small, orange-brown, rectangular chip which at 
one end is rounded. This device can be inserted into periodontal pockets. Each PerioChip® has 
a weight of approximately 6.9 mg and contains 2.5 mg of chlorhexidine gluconate. The 
biodegradable matrix, in which the chlorhexidine is dispersed, consists of hydrolyzed gelatin 
which is cross-linked with glutaraldehyde [81]. 
2.2.3.2.4. Arestin® 
Arestin® is a drug delivery system consisting of microspheres. It is a sustained release 
product into which 1 mg of minocycline hydrochloride has been incorporated. The matrix of 
the delivery system is the bioresorbable polymer PLGA [82]. 
2.3. Lipid drug delivery systems 
In the last 10–15 years, lipid drug delivery received considerable attention in the field of 
pharmaceutical technology. Administration of lipid materials is most prevalent in solubility 
enhancing, lymphatic transport targeting, and/or intestinal transport modulation. Moreover, 
creating sustained release systems, covering the bitter or bad taste of active ingredients or 
protecting drug molecules susceptible to different environmental factors may also be a purpose 
for the application of lipid excipients [83]. 
2.3.1. Lipid-based oral drug delivery systems 
In recent years, several oral, lipid-based systems were successfully marketed. That is why 
there is a considerable interest in these delivery systems. Oral lipid delivery systems can be 
classified into different subgroups: Type I, Type II, Type IIIA, Type IIIB and Type IV. The 
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content of hydrophilic component of formulations is the lowest in Type I and highest in Type 
IV systems [84,85]. 
Delivery systems in the first category (Type I) are the simplest lipid products, which means 
that the active ingredient is dissolved in digestible oil. Triglycerides are easily digested to 
smaller components in the alimentary tract and a colloidal dispersion is formed in the intestines 
from where the passive transport of drug containing micelles can occur [84,85]. 
Formulations in the second category (Type II) contain a lipophilic surfactant which promotes 
emulsification in the gastrointestinal tract. If the system is carefully composed and under 
optimum conditions, a self-emulsifying drug delivery system can be formulated. This means 
that emulsification of the lipid components occurs spontaneously under very gentle conditions. 
The size of the produced particles is 100—250 nm, but it is heavily influenced by the 
concentration and type of the surfactant [84,85]. 
Systems in the third group (Type III) contain hydrophilic surfactants with HLB values over 
12, and other water-soluble components. The difference between Type II and III formulations 
that the hydrophilic components will be dissolved in the aqueous phase after dispersion. They 
can be self-emulsifying or self-microemulsifying drug delivery systems. Type III formulations 
can be further divided into two subgroups Type IIIA and Type IIIB. The difference between 
formulations in group A and group B is that delivery systems in group B have higher 
hydrophilicity, than in group A [84,85]. 
Delivery systems in the fourth group (Type IV) contain large amounts of surfactants (or a 
mixture of surfactants) and co-solvents. There is a high chance that – from these systems – the 
drug will precipitate and form amorphous or very fine crystals in the gastrointestinal tract. 
Concerns has been also emerged in connection with these formulations. Firstly, the dissolution 
of surfactants may take a long time because a gel or liquid crystal phase is formed at the 
interface. Secondly, high concentration of surfactants can irritate the mucosa of the stomach or 
intestine and cause damage [85]. 
2.4. Electrospun drug delivery systems 
The idea of using high voltage to induce formation of liquid drops has been proposed more 
than 100 years ago. The electrospinning process was first patented in 1934, but the procedure 
did not gain commercial success. In the 1990s, interest in this technique was revived and many 
articles have been published in this topic [86–92]. 
Electrospinning is a simple method for generating nano or microscale polymer fibers. This 
technique has received considerable attention in both academic and industrial circles, on the 
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account of its unique ability to produce ultrafine fibers of different materials in various 
assemblies. 
2.4.1. The electrostatic fiber spinning method 
Electrospinning is a method during which a polymeric solution is formed into nano- or 
micro-sized fibers. In more details, a polymer solution in a syringe is dosed by a pump through 
a needle onto which high voltage is applied. The solution flowing through the needle with 
constant flux forms a drop at the end of the needle. Because of the applied high voltage and the 
grounded metal collector, an electric field is generated. This electric field will force the drop of 
polymer solution at the end of the needle to form a cone (Taylor cone). When the electric field 
becomes strong enough to overcome the surface tension, a jet of polymer solution ejected from 
the cone. On its way to the collector plate, the solvent evaporates from the polymer solution, 
and solid fibers are formed [93]. 
Different electrospinning methods exists which were developed from the basic one described 
above. The second generations of electrospinning techniques are side-by-side electrospinning 
and co-electrospinning [94]. 
The third-generation electrospinning technique, multifluidic electrospinning has been 
proposed and the produced electrospun fibers possess multichannel structures or multiple core-
shell structures [94]. 
As the yield of fibers are low due to the limited flow rate and only one needle, a multi-needle 
electrospinning technique has been proposed. This technology may improve the yield of fibers 
which is one of the main research goals of technology [95]. 
The production rate could be largely improved by the elimination of the needle. During 
needle-less electrospinning nanofibers are created from a liquid with an open surface. Self-
organization of the waves of an electrically conductive liquid occurs when electric voltage 
reaches a critical level, and multiple jets are generated [96]. 
2.4.2. Applications of electrospun drug delivery systems 
Electrospun nanoscale fiber may be used for various applications such as air filtration [97], 
oil and water separation [98], water purification, disinfection [99] and even sensory functions 
[100]. 
However, the most important use of electrospun nanofibers is in the medical field as drug 
delivery systems or for tissue engineering purposes. These two areas mostly apply nanofibers 
which were created from biopolymers. Electrospun fibers have been used in vascular, bone, 
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neural and ligament tissue applications [101]. For drug delivery purposes, different kind of 
drugs and biopolymers were investigated to provide sustained release. As the fibers have high 
surface-to-volume ratio, they can provide suitable media for cell binding and cell proliferation, 
and also can increase the drug loading capacity [102]. It is also possible to incorporate proteins, 
DNA, RNA and growth factors into the fibers, while their functionality and bioactivity is 
maintained [103]. 
Electrospun drug delivery systems containing antibiotics may be advantageous in the 
treatment of periodontal disease. In contrast with oral antibiotic treatment, nanofibers could 
provide high concentrations of antimicrobial drugs at the site of infection for an extended time 
period. 
In a study, tinidazole-containing, biodegradable, chitosan/poly(ε-caprolactone) nanofibrous 
systems were created. Tinidazole was released in a sustained manner, while an 18-day bacterial 
growth inhibition could be achieved. The conducted clinical study indicated significant 
decrease in clinical markers of periodontal disease [90]. 
In another study, tetracycline hydrochloride was incorporated into PLGA/gum tragacanth 
nanofibers for periodontal regeneration. Fibers were fabricated via blend and coaxial 
electrospinning. Drug release was prolonged for an outstanding 75 days. Antimicrobial 
effectiveness of these delivery systems were also proven [89]. 
Schkarpetkin and colleagues [91] aimed to prepare nanofibers which contain the 
combination of ampicillin and MZ in a PLA matrix. Fibers were spun via multijet 
electrospinning. Drug release from fibers was sustained for 96 hours and fibers showed 
antimicrobial effectiveness against Aggregatibacter actinomycetemcomitans, Porphyromonas 
gingivalis, Fusobacterium nucleatum and Enterococcus faecalis [91]. 
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3. EXPERIMENTAL AIMS 
The aim of my Ph.D. work was to develop and investigate innovative drug delivery systems 
containing antibiotics for the local treatment or adjuvant local therapy of periodontal disease. 
Two main research approaches were carried out during my work, the first is the development 
of lipid formulations, the second is the formulation and investigation of electrospun drug 
delivery systems for local therapy. 
In the case of lipid-based system, components were selected, and the composition was 
optimized in order to prepare a delivery system which meets the following predefined 
requirements: 
• To contain biocompatible and biodegradable materials. 
• To soften at body temperature which allows the delivery system to accommodate to the 
shape of the periodontal pocket and to leave the periodontal pocket as the gingival tissue 
heals. 
• To have a mucoadhesive feature which helps to maintain the delivery system in the 
subgingival area and, thus, prolong the effect of the active agent. 
• To provide a non-aqueous system in which the incorporated active agent is protected 
against the effects of the environment (oxidization and humidity) and, thus, 
decomposition. 
• To provide sustained release of the API which contribute to a longer antimicrobial effect. 
• To be able to incorporate a wide spectrum of antibiotics or disinfectants to suit the 
individual needs of patients. 
The second research line was focused on the development and characterization of 
nanofibrous electrospun drug delivery systems. The following requirements were set: 
• To have a polymer base which is biocompatible and biodegradable 
• To use an adequate polymeric base which provides sustained release of hydrophilic 
antimicrobial agents. 
An important element of the work was the investigation of the relationship between the 
incorporated API and the bases of the drug delivery systems, and analysis of the antimicrobial 
effectiveness of the formulations. 
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4. MATERIALS AND METHODS 
4.1. Materials 
4.1.1. Active agents incorporated into the delivery systems 
Amoxicillin (AMX) is a semi-synthetic penicillin derivative, is known to be effective against 
many aerobic or anaerobic Gram-positive and Gram-negative bacteria [4,104]. Literature data 
shows that AMX is widely used in the treatment of periodontal disease. 
Metronidazole (MZ) is an antibacterial agent, included in the nitroimidazole group. 
Numerous bacteria and protozoa — even anaerobes — are known to be susceptible to this API 
[5,105]. MZ is also used in the treatment of periodontitis.  
Chlorhexidine gluconate (CHX) is a biguanide antiseptic widely used in the treatment of 
periodontal diseases as mouthwashes. This agent is active against Gram-positive and Gram-
negative organisms, facultative anaerobes, aerobes, and yeasts, and also reduces the build-up 
of plaque and may improve the condition of patients in mild gingivitis. 
Zinc hyaluronate (ZnHA) is a polymer derived from sodium hyaluronate and regularly 
applied in topical gels to accelerate the healing of wounds of different etiologies and to decrease 
the chance of a possible bacterial superinfection [106]. It may be used as a mucoadhesive agent 
in ophthalmic solutions to lengthen clearance and provide higher efficiency [107]. Moreover, 
hyaluronic acid shows anti-inflammatory effects [108], which makes it suitable for the 
treatment of periodontal diseases. That is why this component was also used in the formulations 
as a gelling and mucoadhesive agent and to provide an antimicrobial effect. 
Zinc gluconate (ZnGlu) is a zinc salt with a known anti-microbial effect. It is often used in 
combination with zinc hyaluronate in order to increase the antimicrobial effect. 
4.1.2. Materials used for the lipid-based systems 
Cetostearyl alcohol (CA) was used as a potential structure-building component. It is mostly 
used as a surfactant, a co-surfactant or as a viscosity increasing agent in semisolid formulations. 
The melting range of the pure component is between 48—56 °C [109].  
White beeswax (WB) was also used as a potential structure-building component. It is a 
chemically bleached natural beeswax which consists of esters of C24 to C36 straight-chain 
alcohols and straight-chain acids. It is used in creams, oils, ointments to increase consistency 
and in emulsions as a stabilizer. According to the literature, its melting point is between 60—
67 °C [109]. 
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Lipophilic Suppocire BP (SBP) was chosen as a lipid base. It has a melting range between 
36—37 °C and a hydroxyl value between 30 and 50. In most cases, it is used as a base for 
suppositories [109]. 
Methocel E4M (hydroxypropyl methylcellulose, HPMC) was used as a gelling and 
mucoadhesive component. HPMC is often used as a mucoadhesive agent in oral formulations 
such as films [110] or buccal tablets [111] to increase the residence time of the delivery system. 
This component also helps the water penetration into the systems thus the erosion and the 
diffusion of the active agent. 
Kolliphor RH40 (KP) was used as a wetting agent. This is a polyoxyethylene 40 castor oil 
derivative and can be used as an emulsifying or wetting agent. Literature data shows that it has 
a congealing temperature between 16 and 26 °C, and a melting point approximately at 30 °C 
[109,112]. 
4.1.3. Materials used for the electrospun nanofibrous systems 
For the PLA-based fibers polylactic acid (PLA) (Ingeo 4032D type, NatureWorks LLC., 
Minnetonka, MN, USA), dichloromethane, dimethyl sulfoxide (Molar Chemicals Ltd., 
Halásztelek, Hungary) and metronidazole (Ph. Eur. 8., Hungaropharma Plc., Budapest, 
Hungary) were used. 
Polylactic acid is an aliphatic polyester, which can be derived from renewable sources i.e. 
plants. In terms of physical properties, PLA can be crystalline, semi-crystalline or highly 
crystalline. Glass transition of this material is between 60 and 65 °C and melting point is 130—
180 °C. 
PLA is often referred to as a bioplastic because it is a biodegradable polymer, and in the 
medical field, it is used to create absorbable sutures, bioabsorbable implants for orthopedics 
and systems for controlled drug delivery of active agents [113]. To create the nanofibers PLA 
(Ingeo 4032D type, NatureWorks LLC., Minnetonka, MN, USA) was used. 
4.2. Methods 
4.2.1. Preparation of lipid-based systems 
All the formulations were created by a melting and homogenation method. Firstly, the two 
lipophilic components (CA and SBP) and the surfactant (KP) were melted together at 70 °C on 
a hot plate, then the polymer (ZnHA or Methocel E4M) was suspended and homogenized with 
an overhead stirrer at 50 RPM. The components of drug free compositions for the 
preformulation studies can be seen in the Table 2. 
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Table 2. Composition of formulations analyzed during the preformulation studies of lipid-based delivery systems. 
Concentration of the components (m/m%) 
Structure-building 
component 
Lipid base Surfactant Polymer 
WB CA SBP KP 
Methocel 
E4M 
10 0 85 5 0 
10 0 80 10 0 
10 0 75 15 0 
10 0 70 20 0 
0 5 90 5 0 
0 5 85 10 0 
0 5 80 15 0 
0 5 75 20 0 
20 0 67 10 3 
40 0 47 10 3 
60 0 27 10 3 
0 20 67 10 3 
0 40 47 10 3 
0 60 27 10 3 
In the case of the formulation studies for the drug delivery sytems, the antimicrobial agent(s) 
(AMX, MZ, ZnGlu) was/were dispersed and homogenized at 50 °C to avoid thermal 
decomposition. Delivery systems were created by molding the melted formulations into round 
shaped silicone molds. Cylindrical drug delivery systems were 1.5 mm in thickness and 9 mm 
in diameter. 
In Table 3, the composition of the drug delivery systems is shown. A unique code has been 
assigned to each individual formulation [109,114]. 
Table 3. The composition of lipid-based delivery systems. 
 Composition of delivery systems (m/m%) 
Components F1 F2 F3 F4 F5 F6 F7 
SBP 32 32 32 47 46.8 32 42 
CA 40 40 40 40 40 40 40 
KP 10 10 10 10 10 10 10 
Methocel E4M 3 3 3 - - - 3 
MZ - 15 7.5 - - 15 - 
ZnHA - - - 3 3 3 - 
AMX 15 - 7.5 - - - - 
ZnGlu - - - - 0.2 - - 
2% CHX solution       5 
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4.2.2. Preparation of PLA-based nanofibrous drug delivery systems 
PLA-based systems were produced at the Budapest University of Technology and 
Economics in the Laboratory of Plastics and Rubber Technology. The production parameters 
were briefly the following: fibers were spun at ambient temperature at 15 kV voltage, 10 cm 
collector distance and a feeding rate of 3 cm3/h, from the 80/20 v/v% mixture of 
dichloromethane and dimethyl sulfoxide. The solution contained the polymer in 10 m/m%, 
while the amount of the active component was changed from 0 to 3 m/m% of the solution. 
The fibers were investigated as native fibers and as compressed disks. Neat electrospun fiber 
mats were taken directly from the aluminum collector film and round-shaped disks were 
obtained by compressing approximately 10–15 mg of the neat fiber under 1 kN pressure for 
30 s in a pellet die of 13-mm diameter. 
4.2.3. Investigation of drug delivery systems 
4.2.3.1. Optical contact angle measurements 
The behavior of the drug delivery systems in contact with aqueous media was studied with 
an OCA Contact Angle System (Dataphysics OCA 20, Dataphysics Inc., GmbH, Germany). 
The contact angle of water droplets was determined. The measurement was done with a water 
droplet of 10 μL volume, which was dropped from a calibrated syringe onto the surface of the 
various delivery systems. 
In the case of lipid-based delivery systems, contact angles were measured immediately after 
contact. Five parallel measurements were performed on each sample. 
PLA-based native fibers and compressed disks were measured in a similar way, but contact 
angles of droplets were measured immediately after, and 10 and 20 minutes subsequent to 
droplet placement, as well. Five parallel measurements were carried out. 
4.2.3.2. Differential scanning calorimetry of lipid-based systems 
The softening temperature and the melting point of the lipid formulations were determined 
by differential scanning calorimetry measurements with a Mettler-Toledo DSC 821e instrument 
in argon atmosphere (100 mL/min). The temperature was raised from +5 °C to +100 °C by 5 
°C per minute. 10 mg of the samples were put in 40 µL aluminum pans. The tops were holed, 
then the pans were sealed. 
Two sets of measurements were carried out: during the preformulation studies formulations 
without active agents were analyzed, while during the characterization of API containing 
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formulations, the effect of the incorporated active agent on the melting point and softening 
temperature was investigated. 
4.2.3.3. X-ray diffraction (XRD) measurements 
The solid state of the components was analyzed by means XRD measurements. A Bruker 
D8 Advance diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) with CuKα radiation 
(λ = 1.5406 Å) was used for the XRD analysis. The samples were scanned at 40 kV and 20 mA 
from 3° to 40° 2θ angle at a scanning rate of 0.1 °/s and a step size of 0.01°. 
4.2.3.4. Hardness of lipid-based systems 
The hardness of lipid-based formulations was investigated by a TA.XT Plus C texture 
analyzer. During the measurements, a probe 50 mm in diameter penetrated 0.5 mm into the 
formulations. The evaluation was carried out in different circumstances: at room temperature 
(25 °C) and after 10 minutes of immersion into 1 mL of water at body temperature (37 °C). 
Three parallel measurements were carried out. 
4.2.3.5. In vitro drug release tests 
4.2.3.5.1. Lipid-based systems 
The in vitro drug release profiles of the delivery systems were determined. The compositions 
were weighed with an analytical scale, put in 50-mm-long dialysis tubes (Spectra/Por® 
Standard RC tubing, MWCO: 12-14 kD) and sealed with closures. The tubes containing the 
formulations were placed in 7.5 mL of PBS solution (prepared by dissolving 8 g/dm3 NaCl, 0.2 
g/dm3 KCl, 1.44 g/dm3 Na2HPO4 · 2 H2O and 0.12 g/dm3 KH2PO4 in distilled water and the pH 
was adjusted to 7.4 by adding an adequate amount of 0.1 M HCl) thermostated at 37 °C. Drug 
release was investigated for seven days, and three parallel measurements were carried out. One 
milliliter of sample was taken (at 0.5, 1, 2, 4, 6, 10, 24, 30, 48, 72, 96 and 168 h) and replaced 
with 1 mL of fresh PBS solution thermostated at 37 °C. 
CHX was quantified by UV spectrophotometric analysis at 250 nm, while AMX and MZ 
were analyzed with Merck-Hitachi LaChrome Elite HPLC (Hitachi High Technologies 
America, Inc., Schaumburg, IL, USA) using UV detector at 230 nm. The column was a Kinetex 
250 mm × 4.6 mm column packed with 53 µm EVOLuna C18, 100 Å (Phenomenex Inc., 
Torrance, CA, USA). Isocratic elution was performed with 20:80 (v/v) Methanol-NaH2PO4 
(0.05 M) at a flow rate of 1 mL/min. Retention time for AMX and MZ was at 4.6 and 6.7 
minutes, respectively. The resolution (RS) was 3.10. 
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4.2.3.5.2. PLA-based nanofibers 
The in vitro drug release profiles of PLA nanofibers were determined by the measurement 
of dissolution followed by UV-Vis spectroscopy (Helios α Thermospectronic UV-
spectrophotometer v4.55, Unicam: Thermo Fisher Scientific, Waltham, MA) at 318 nm. Disks 
(0.014—0.017 g) and neat fiber mats (0.012—0.016 g) were weighed and put into 7.5 mL of 
pH=7.4 PBS solution thermostated at 37 °C. Samples of 1.0 mL volume were taken at 0.5, 1, 
4, 6, 10, 24, 30, 48, 72, 96 and 196 hours and replaced with 1.0 mL of fresh PBS solution. Drug 
release was followed for 7 days. 
4.2.3.6. Antimicrobial effectiveness of formulations 
Typical periodonthopathogenic bacteria, namely F. nucleatum (ATCC 25586), Parvimonas 
micra (ATCC 33270), Eikenella corrodens (ATCC 23834), P. gingivalis (ATCC 33277), A. 
actinomycetemcomitans (ATCC 29524) and Prevotella intermedia (clinical isolate no. 118710) 
control strains were used. (In the case of nanofibrous drug delivery systems the measurements 
with P. gingivalis could not be carried out, because the previously used control strain showed 
no sign of growth, and no other control strain was available.) A 1 McFarland standard 
concentration bacterial suspension of each bacterial strain was made separately with 0.9% NaCl 
solution (in suspension it is equivalent to approximately 3×108 colony forming units/mL). The 
suspension was spread onto a horse blood agar plate, where then formulations were placed on. 
After 24 hours of incubation in anaerobic conditions (Concept 400 anaerobic incubator, 
Biotrace International Plc., UK), the diameter of the inhibition zones was measured. The 
formulations were then put on a new horse blood agar plate, also inoculated with 1 McFarland 
standard concentration freshly made bacterial suspension of each of the above-mentioned 
bacterial strains. The plates were then put in an anaerobic chamber for 24 hours. This was 
repeated until no inhibition zone could be detected. 
In our microbiological investigations, the antimicrobial activity of our formulations was 
measured on six different strains of oral pathogenic bacteria which may contribute to the 
initiation of periodontitis. As mentioned above, these were the following: E. corrodens, P. 
intermedia, P. micra, F. nucleatum, A. actinomycetemcomitans and P. gingivalis. 
E. corrodens – a facultative anaerobic, Gram-negative bacterium – is a human (mostly oral) 
pathogen. E. corrodens appears to be susceptible to beta-lactam antibiotics, but resistant to MZ 
[115]. 
P. micra (previously known as Peptostreptococcus micros or Micromonas micros) – an 
anaerobic, Gram-positive coccus – is the member of the normal human gastrointestinal flora 
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[116]. According to Rams et al., it shows high susceptibility to penicillin, but MZ seems to be 
less effective against the bacterium [117]. 
P. intermedia – a Gram-negative anaerobic bacterium with black pigments – is often 
connected with oral and subgingival diseases. P. intermedia shows susceptibility to beta-lactam 
antibiotics and MZ [118]. 
F. nucleatum – a predominantly oral and periodontal anaerobic pathogen – can be linked to 
a variety of human diseases. Strains isolated from endodontic infections seem to be highly 
sensitive to AMX and to a lesser extent to MZ [119,120]. 
A. actinomycetemcomitans – a Gram-negative, facultatively anaerobic rod – is frequently 
associated with most forms of periodontitis and numerous oral infections. AMX is effective 
against the bacterium, while it shows much less susceptibility to MZ [121,122]. 
P. gingivalis – an obligately anaerobic, Gram-negative black-pigmented rod – is the most 
commonly linked microorganism to periodontal disease. According to susceptibility tests, P. 
gingivalis is susceptible to AMX and MZ [123,124]. 
5. RESULTS AND DISCUSSION 
5.1. Lipid-based systems 
The aim of this part of my thesis was to create a local, swellable, degradable drug delivery 
system with the following requirements: a) to soften but not totally melt at body temperature; 
b) to accommodate to the shape of the periodontal pocket; c) to have proper wetting properties 
in order to aqueous media be able to access the incorporated materials; d) to swell in an aqueous 
environment, which contribute to the erosion and elimination of the delivery systems; e) to have 
a mucoadhesive feature; f) to be effective against microorganisms responsible for periodontal 
disease; and g) to provide extended drug release [109,114]. 
The approach to the satisfaction of these requirements was to formulate a hydrophobic 
matrix which has a lipid base, contains a structure-building component, a polymer, and a 
surface-active agent. Proper choice of these excipients could provide the delivery systems with 
other features such as swelling, erosion, or has a soft but coherent structure. 
Incorporation of hydrophilic antimicrobial agents into a hydrophobic matrix could protect 
the antimicrobial agents and hinder penetration of aqueous media into the devices, and, thus, 
allowing sustained release of drugs.  
According to the abovementioned requirements, the following components were selected. A 
lipid base with a melting point at body temperature (Suppocire BP (SBP)) was chosen. 
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Structure-building components were selected to prevent total melting of formulations (white 
beeswax (WB) and cetostearyl alcohol (CA)). A surface-active agent was picked to help the 
wetting of formulations (Kolliphor RH40 (KP)). Different polymers were used to aid water 
penetration into the formulations, and swelling and erosion of lipid systems, and to provide a 
mucoadhesive feature to formulations (Methocel E4M and zinc hyaluronate (ZnHA)). 
Antimicrobial agents were incorporated into the systems to provide antibiotic effect 
(amoxicillin (AMX), metronidazole (MZ), chlorhexidine gluconate (CHX), zinc gluconate 
(ZnGlu) and zinc hyaluronate (ZnHA)). 
The abovementioned active agents were used alone (AMX, MZ, CHX or ZnHA) or in 
combination with another agent. Formulations were created with the combination of AMX and 
MZ; ZnHA and ZnGlu; and ZnHA and MZ. The delivery systems into which ZnHA was 
incorporated, did not contain HPMC, because ZnHA also possesses mucoadhesive features. 
5.1.1. Preformulation study 
During the preformulation study, different measurements were carried out to determine the 
suitable concentration and the type of the structure-building component. The concentration of 
the surface-active agent and the polymer were also determined. 
DSC measurements were used to analyze the effect of different structure-building 
components and their concentration. The effect of surface-active agent concentration on the 
melting point of the formulations was analyzed, as well. 
Wettability of formulations was also investigated to confirm the chosen concentration of the 
surfactant and the polymer. The wetting of the formulation with the surrounding media is 
crucial for the future drug release; therefore, it is an effort to provide an ideal contact angle 
between the system and the aqueous medium. 
Cetostearyl alcohol was chosen as a structure-building component, as formulations 
containing white beeswax – independent of the concentration of white beeswax – disintegrated 
after one day of immersion in water at body temperature, which could result in a too fast drug 
release. 
DSC measurements indicated that the best softening range of formulations may be achieved 
if the concentration of cetostearyl alcohol is fixed at 40 m/m%. The concentration of the 
surface-active agent did not influence the softening and melting point of formulations. 
By wettability measurements the concentration of the surface-active agent was determined. 
Best wettability of formulations could be achieved if the concentration of the surface-active 
agent was at 10 m/m%. 
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The concentration of the polymers was determined by wettability measurements as well. 
Results indicated that 3 m/m% of Methocel E4M and 3 m/m% of ZnHA is suitable for the 
delivery systems. 
The concentration of SBP – the lipid base – and the active agent together was always held 
at 47 m/m%. The concentration of APIs was either determined by a preliminary antimicrobial 
investigation or literature data analysis. 
To conclude the results of the preformulation study, CA was chosen as the structure-building 
component. Its concentration was held at 40 m/m%. The concentration of KP – the surface-
active agent – was determined to be 10 m/m%. 3 m/m% of polymers were incorporated into the 
delivery systems. The sum of the concentration of the lipid-base and the antimicrobial agent 
was 47 m/m%. 
Formulations shown in Table 2 were the drug delivery systems of which further evaluation 
were carried out. 
5.1.2. Evaluation of lipid drug delivery systems 
Further evaluation of delivery systems with incorporated active agents were carried out to 
analyze the effect of the incorporated antimicrobials on the melting point and softening 
temperature of formulations. The state of the APIs was also investigated along with the 
consistency of delivery systems and the possibility of sustained drug release. Effectiveness of 
formulations against bacteria was also determined. 
5.1.2.1. Differential scanning calorimetry of formulations 
DSC method was employed to analyze if the incorporated active agents modify the softening 
temperature or melting point of the delivery systems. DSC curves of the formulations can be 
found in Figure 4. 
The lipid base of the compositions was SBP which has a melting point at 39.08 °C according 
to our measurements. CA, which was used as the structure-building component of the 
formulations, had a melting point at 61 °C. The results of DSC measurements show that KP has 
a congealing temperature approximately between 20—30 °C, which corresponds with the 
literature data. No sharp peaks could be perceived on the curves belonging to the polymers 
(ZnHA and Methocel E4M), and zinc gluconate in this temperature range (10—100 °C). 
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Figure 4. DSC curves of bases and different formulations F1—F7. 
Formulations F1–F7 were examined to investigate the possible modifying effect of the 
incorporated drugs and excipients on melting point. Antibiotics or other suspended materials 
may partially dissolve in the lipid base, therefore, the effect of various incorporated components 
of different amounts on the melting point was also investigated. In all formulations, the sharp 
peaks of SBP and CA disappeared, even the two peaks of CA morphed into one, and shifted to 
temperatures between the melting points of the two pure components. At approximately 30 °C, 
a moderate melting can be observed, but total melting only occurs between 40 and 50 °C. This 
moderate melting supports the softening of the systems, but, the presence of components with 
melting points at about 50 °C suggests the existence of a coherent structure at body temperature. 
By the thorough analysis of the DSC results, it could be concluded that no peaks of any curve 
belonging to different formulations could be associated with the decomposition of any 
component, thus, the constituents are expected to be stable in this temperature range. Moreover, 
incorporated active agents did not influence the melting point highly, and the softening 
temperature of the formulations in the preformulation studies are held. 
5.1.2.2. Evaluation of hardness 
Measurement of the hardness of formulation F7 (CHX) was carried out in order to analyze 
the deformability and consistency of the drug delivery systems in different circumstances (at 
room temperature in a dry state; and at body temperature in an aqueous environment which 
imitates the insertion into the periodontal pockets). In this texture analysis, a spherical probe 
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with a diameter of 5 mm penetrated 0.5 mm into the formulations. This means that the force is 
measured which is needed for the approximate 50% deformation of the delivery systems. 
 
Figure 5. Hardness of formulation F7 in different conditions: at 25 °C in a dry state and at 37 °C in aqueous media. 
According to the results displayed in Figure 5, 2074 ± 48 mN force is needed to deform the 
delivery systems at room temperature. When the formulations were held at 37 °C in aqueous 
media, this force dropped down to 810 ± 116 mN. 
The decrease of force needed to deform the delivery systems indicates that the structure 
suffered a considerable softening, but coherent forces of the structure-building component did 
not cease entirely. Results are in conjunction with the results of DSC analysis and confirm that 
total melting of formulations do not occur at body temperature; therefore, the delivery systems 
can stay at the site of infection (at the subgingival area), can accommodate to the shape of the 
periodontal pockets (PP) and can provide sustained release of antimicrobial drugs. 
5.1.2.3. X-ray diffraction analysis 
XRD analyses were carried out to investigate the state of the antibiotic drugs. The presence 
of solid crystals is indicated by sharp peaks in the diffractograms, while molecularly dispersed 
or amorphous components, as they do not possess a crystalline structure, are not shown. The 
amorphous structure is often a substantial feature of polymers; thus, a crystalline structure is 
absent and characteristic diffractograms can rarely be obtained. 
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Figure 6. Diffractogram of pure components (Kolliphor RH40 (KP), Suppocire BP (SBP) and cetostearyl alcohol (CA), 
amoxicillin (AMX), metronidazole (MZ), zinc hyaluronate (ZnHA), zinc gluconate (ZnGlu), Methocel E4M, and chlorhexidine 
CHX) and formulations F1—F7. 
All of the components, except HPMC, KP, ZnHA, and ZnGlu, have a crystalline structure 
according to the XRD diffractograms presented in Figure 6. 
SBP and CA have similar molecular structures, which will result in analogous 
diffractograms. This means that in the diffractograms of the formulations containing all of the 
components, it is hard to differentiate between the two lipid components, SBP and CA during 
the evaluation of the different formulations. The more intensive peak of CA could overlap with 
and cover the peak of SBP at the same 2θ value in the preparations. This peak, which belongs 
to CA, has decreased in intensity in the diffractograms of the formulations, which implies that 
the crystallinity of CA has suffered a setback, which is in accordance with the DSC results, 
where the two peaks of pure CA have fused together and shifted to a lower temperature range. 
A characteristic peak linked to SBP at the 2θ value of approximately 5° is present in all 
formulations with varied intensity. 
The characteristic peaks of AMX and MZ could be separated from those of the lipid 
components. The presence of characteristic peaks in the diffractograms is the sign of solid 
particles in the formulations. AMX and MZ have a characteristic peak at the 2θ value of 
18.1°and 12.3°, respectively. Peaks of AMX or MZ at the mentioned 2θ values could be 
observed in the diffractograms of formulations F1 (AMX), F2 (MZ), F3 (AMX+MZ) and F6 
(MZ+ZnHA). 
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The presence of ZnHA or ZnGlu in the preparations could not be demonstrated by this 
experiment because of their amorphous structure, to which no characteristic peaks belong in an 
XRD diffractogram. 
Interestingly, characteristic peaks of CHX cannot be seen in the diffractogram of F7 (CHX). 
There may be more, than one explanation to this phenomenon. Firstly, CHX may be dissolved 
in the lipid base of the delivery systems. Secondly, CHX may be still dissolved in the aqueous 
phase which is emulsified with the lipid components. Thirdly, CHX may have precipitated from 
the aqueous solution – when it was added to the melted lipid components –and the precipitated 
crystals are suspended in the lipid base. However, the concentration of crystalline CHX is below 
the limit of detection of the applied method. 
The partially crystalline form of the lipid matrix (CA and SBP) could contribute to the 
coherent structure of the system, which does not melt at body temperature, thus providing 
sustained release of antibiotic compounds. 
5.1.2.4. Drug diffusion from the delivery systems 
Drug dissolution measurements were carried out in order to evaluate the drug release profiles 
of the prepared formulations which contain MZ (F2, F3 and F6) or CHX (F7). Delivery systems 
were put into dialysis tubes, and MZ was quantified by an HPLC method, whereas CHX was 
quantified by UV-Vis spectrophotometry. 
The amount of released MZ is shown in Figure 7. Formulations F2 (MZ) and F6 
(MZ+ZnHA) have shown similar drug release profiles. A plateau phase commences at 
approximately the 100th hour in both cases, which is in accordance with a total drug release. 
However, the drug release curves of formulation F3 (AMX+MZ) indicates that only one-
third of the amount was liberated from the preparations despite that half of the amount had been 
incorporated into the compositions. 
MZ, which is a more soluble material in water compared to AMX, could be liberated more 
quickly from formulations creating capillaries, which contribute to a higher swelling and 
therefore allow water to access all the suspended drug in the delivery systems. On the contrary, 
when smaller amounts of MZ are incorporated into the delivery systems with AMX – a 
substance with lower water solubility – fewer capillaries may be formed during drug release, 
permitting less water to penetrate the systems and resulting in non-complete drug dissolution. 
The application of ZnHA did not change the release profile, which can be explained by the 
similar swelling and degradation profiles of formulations F2 (MZ) and F6 (MZ+ZnHA). 
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Figure 7. The amount of metronidazole diffused from formulations F2, F3, and F6. 
In the case of formulation F7 (CHX) during the one-week (170.5 hour) investigation period, 
approximately 225 µg of active agent diffused from the delivery systems, which is nearly 50% 
of all incorporated drug (Figure 8). On average, 19% (83 µg) of all incorporated CHX diffused 
from the delivery systems during the first 24-hour period. A plateau phase could not be observed 
during the test length, which indicates that the release continues after 1 week. 
According to Figure 8., the amount of drug diffused from formulation F7 during one week 
is approximately 50% of all incorporated drug, which indicates sustained release. Bakó and 
colleagues investigated the diffusion of CHX from PerioChip® [125], which is also a CHX-
containing drug delivery system, in different pH conditions. Comparing their results in pH 7.4 
PBS solution to the results of our in vitro drug diffusion measurements, it can be concluded that 
formulation F7 provides a continuous release, while in the case of PerioChip® a burst release 
can be observed (40% of drug released during 24 hours). This burst release is followed by a 
slow release which results in 27% more released drug at the end of the 1-week observation 
period. This indicates that our formulated CHX containing lipid-based systems can provide a 
continuous release at a higher but steady rate. 
Summarizing the results of drug diffusion testing, a sustained release of drugs could be 
achieved with these compositions, and the main factors affecting drug release are swelling 
(driven by the applied hydrophilic components such as polymer, active ingredients and their 
concentration) and the strength of the coherent lipid structure. 
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Figure 8. The amount of chlorhexidine diffused from formulation F7. 
5.1.2.5. Antimicrobial effectiveness of formulations 
Numerous different species of microorganisms may be present in the oral cavity or on the 
dental surfaces. The composition of the oral microbiota varies widely from person to person, 
from place to place and naturally with dietary habits [126,127]. 
According to Kolenbrander and colleagues [128], these species can be separated into two 
categories concerning plaque formation. Species in the first category (initial colonizers) are 
thought to stick to the tooth surface and proliferate. The second group (late colonizers) binds to 
the first group of bacteria via different interactions. 
Hyaluronic acid (HA) is a naturally occurring polysaccharide of the extracellular matrix of 
connective tissue, synovial fluid, and soft periodontal tissues as well. Its application in the 
treatment of the inflammatory process is established in different medical areas such as 
orthopedics, dermatology, and ophthalmology. In the treatment of periodontal diseases, 
hyaluronic acid shows anti-inflammatory effect [129], whereas the zinc salt of HA possesses 
an antimicrobial effect [114]. 
Zinc salts may have a beneficial effect when used in mouth rinses, can possibly decrease 
plaque formation by inhibiting glycolytic enzymes and may prevent the attachment of bacteria 
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to the tooth surface [130]. These salts administered in combination with other antimicrobial 
agents may show a synergism by means of antibacterial effect [131]. 
In our microbiological investigations, the inhibition zone of the formulation was measured 
using fresh agar plates day-by day. The length of the inhibition was evaluated in case of the 
different formulations, the results can be found in Figure 9. 
According to our measurements, P. micra was the most sensitive microorganism to AMX 
containing formulations as the compositions could provide 18 days of effective drug release, 
while the least susceptible pathogen was E. corrodens with only 9 days of growth inhibition. 
MZ susceptibility was slightly lower, as the effect against the most sensitive bacterium P. 
gingivalis was only nine days. E. corrodens was the least susceptible to MZ as on the first 2 
days no growth could be detected, but after two days there was no inhibition zone around the 
formulation. This result is in accordance with the literature data, where it was established that 
E. corrodens is resistant to MZ [132]. 
Formulation F3 (AMX+MZ) did not provide larger inhibition zones than formulations 
containing only one antimicrobial agent as the antimicrobial effect lasted for a shorter time. P. 
gingivalis was an exception: this bacterial strain was the only one with higher susceptibility to 
the combination of AMX and MZ. 
In most cases, the growth inhibition effect of combinations lasted longer than that of MZ. 
This could have been possible due to the more potent antimicrobial effect of AMX. Lower 
susceptibility to the combination of AMX and MZ compared to only AMX containing 
formulations may be due to the decreased concentration of AMX in the formulation F3 
(AMX+MZ) and the lower susceptibility of bacteria to MZ. 
Susceptibility to ZnHA is different among various bacterial strains. A. 
actinomycetemcomitans and E. corrodens show resistance to ZnHA, but combined with ZnGlu, 
a longer effect can be observed in case of A. actinomycetemcomitans. E. corrodens remains 
unsusceptible to the combination of ZnHA and ZnGlu. 
According to the results, the same susceptibility characterizes P. gingivalis and P. intermedia 
when using ZnHA alone or in combination with ZnGlu. In case of P. micra and F. nucleatum, 
the results show that higher efficiency may be achieved by administering a combination of 
ZnHA and ZnGlu instead of using only ZnHA. 
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Figure 9. Time of bacterial growth inhibition of formulations F1—F7. 
The results imply that the combination of MZ and ZnHA provides a synergistic effect: 
formulations containing both ZnHA and MZ provided longer growth inhibition against the 
microorganisms than the active agents alone. The synergistic effect is most conspicuous against 
E. corrodens where formulations with MZ only having a two-day inhibitory effect, and ZnHA 
had no antibacterial effect against the bacteria, while the combination showed a nine-day effect. 
The outcome of the antimicrobial investigation of ZnHA supports that alone it may not be 
effective enough, but a combination with an antimicrobial drug(s) (e.g., MZ) may provide a 
synergistic and – in this case – a longer positive effect. 
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Formulation F7 (CHX) has effectively inhibited the growth of all used bacteria. The least 
susceptible strain was A. actinomycetemcomitans (10 days of growth inhibition), while the most 
susceptible was F. nucleatum and P. micra (15 days of growth inhibition). These results indicate 
why is CHX is still used in the everyday dental practice. 
All in all, it can be concluded that formulations F1 (AMX), F6 (MZ+ZnHA) and F7 (CHX) 
were the most effective against these six bacterial strains. ZnHA alone may not be effective, 
but in combination with ZnGlu they may be active against susceptible bacteria. In contrast with 
literature data, the combination of AMX and MZ did not provide the expected effectiveness. 
Formulation F2 (MZ) has also showed mild growth inhibition but with formulation F6 (CHX) 
longer inhibition of bacterial growth could be achieved. 
5.1.3. Summary of the formulated lipid-based drug delivery systems 
To summarize the first part of my experimental work, it can be concluded that: 
• By using DSC and OCA measurements, the optimal composition of the lipid-based 
systems and the proper structure-building component was identified during the 
preformulation study: 40 m/m% CA, 10 m/m% KP, 3 m/m% polymer (ZnHA or 
HPMC) were chosen. The sum of the concentration of SBP and the incorporated 
active agent is fixed at 43 m/m%. This composition is able to provide a softening at 
body temperature and sustained release of incorporated materials. 
• DSC investigation of drug loaded formulations indicated that incorporation of active 
ingredients does not influence highly the softening and melting point of the 
formulations. 
• XRD measurements proved that the incorporated materials are mostly suspended in 
crystalline form in the lipid base. 
• Swelling and erosion of formulations were confirmed during my PhD work [114]. 
Swelling and erosion profiles depend on the incorporated materials, their attributes 
and the coherent lipid structure. 
• In vitro drug release measurements confirmed that sustained drug release of 
incorporated active agents is possible. 
• Antimicrobial effectiveness investigations revealed that the formulations provide 
long-term effectiveness against anaerobic pathogen bacteria responsible for the 
initiation of the disease. 
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• The investigation of antimicrobial effect on anaerobic bacteria showed that the 
highest effectiveness can be reached by the incorporation of AMX, CHX or the 
combination of MZ and ZnHA. 
5.2. Electrospun drug delivery systems 
5.2.1. Sample preparation 
The MZ concentration of the fibers was 12.2 and 25.7 m/m%, the latter corresponding to the 
MZ concentration of the saturated spinning solution. Neat electrospun fiber mats taken directly 
from the aluminum collector film and round-shaped, compressed disks were obtained by 
compressing approximately 10—15 mg of the neat fiber under 1 kN pressure for 30 seconds in 
a pellet die of 13 mm diameter. Samples are shown in the pictures in Figure 10. 
 
Figure 10. Neat fibers (A) directly from the collector and compressed disks (B) obtained by compression of neat fibers. 
5.2.2. Scanning electron microscopy 
The structure of the fiber mat and the disks was also studied by scanning electron 
microscopy. Micrographs showing the differences in structure are presented in Figure 11. The 
mat consists of loose fibers with considerable space among individual fibers (Figure 11 A). One 
would expect fast penetration and easy flow of the fluid used for dissolution and thus very fast 
release of the drug. The scrutiny of micrographs recorded on mats reveals the presence of MZ 
crystals among the fibers. The structure of a disk is shown in the micrograph of Figure 11 B). 
The disk has a much more compact structure, voids are smaller, and the fibers are close to each 
other. The presence of MZ crystals among the fibers is more obvious in this case. The SEM 
A) B) 
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study proves that a part of the drug is distributed in crystal form among and probably also within 
the fibers. 
 
Figure 11. SEM micrographs recorded on the PLA devices studied. A) fiber mat, B) compressed disk. The black dots are 
crystalline metronidazole particles in picture B). 
5.2.3. X-ray diffraction analysis 
XRD analyses of native and pressed samples prior to and after dissolution testing were 
carried out to investigate the crystalline structure of the incorporated MZ and the PLA fibers. 
MZ-containing and blank devices were analyzed. Both native and compressed fibers were 
included in the investigation. Diffractograms are shown in Figure 12. 
Characteristic peaks of MZ appear in the diffractograms of all metronidazol-containing 
fibers at approx. 13.8 and 14.9 2θ, only the intensity varies with the concentration. 
Diffractograms of PLA fibers without incorporated API show that electrospun PLA 
filaments have a semi-crystalline structure (2θ of peak is approx. 16.5), which was held and 
was more expressed (higher peaks and broader areas) when MZ was added to the systems. 
However, a decreased peak area and intensity could be observed after the dissolution test, 
indicating a decrease in the crystallinity of the semi-crystalline structure of the polymer. 
The intensity of characteristic peaks belonging to MZ decreases during the dissolution 
experiment as an effect of drug release. It can also be seen that some MZ remains in the device 
even after the dissolution experiment, which indicates that some of the drug precipitates during 
fiber spinning and crystals are located not only among, but also within the fibers. The release 
of this latter part of the drug is quite slow and does not take place in the time scale of the 
dissolution experiment. 
A) B) 
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Figure 12. XRD diffractograms of native fibers and compressed disks before and after in vitro drug release measurements. 
5.2.4. Wettability analysis 
In order to gain insight related to the penetration of the dissolution medium into the devices 
prepared, the contact angle of water was measured on the formulated native fibers, and the 
compressed disk and MZ as a function of time. The results are presented in Table 4. Contact 
angle is measured by placing a droplet of a liquid onto a smooth, stable surface. MZ dissolves 
in water, while both the fiber mats and the compressed disks have rough, porous surfaces into 
which the liquid may penetrate. Accordingly, the contact angle measured depends on the rate 
of dissolution in the case of MZ, and on surface tension and surface morphology in the case of 
the two devices. Pore size and capillary forces also play an important role in the formation of 
contact angle, but also in the rate of drug release. Since the surface tension of the components 
is constant and we do not expect large changes in the surface tension of PLA as an effect of the 
dissolution of some MZ in it, the major factors in the development of contact angle must be 
morphology, porosity and capillary forces. 
According to the results Table 4, the contact angle of water on the MZ pastille is small, 
which is not surprising because MZ dissolves in water. Dissolution is confirmed by the fact that 
contact angle could not be measured after 10 minutes of forming the droplet on the surface. 
Contrary to MZ, the contact angle of the droplet placed onto the fiber mat is quite large, 
indicating poor wetting and penetration. Contact angle does not change with MZ content; the 
differences are caused by changes in morphology and the standard deviation of the 
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measurements. Contact angles showed just a slight systematic decrease with time for the neat 
fiber mats, indicating that water can slowly penetrate into the mat. 
Table 4 Contact angles measured (mean and SD values) on a metronidazole pastille and on drug release devices (fiber mats, 
disks) at various times. 
The contact angle measured on the compressed disks is much smaller and it is independent 
of the concentration of MZ as well. It decreases considerably with time and could not be 
measured after 10 min at all, showing that the water droplet placed onto the disk disappeared 
in this time interval. The difference in the contact angles measured on the fiber mat and the 
compressed disk proves that the primary factor determining aqueous media penetration is 
morphology and this factor is expected to determine the extent and rate of drug release as well. 
The apparent contradiction that water cannot penetrate so fast into the loose fiber mats, while 
it does into the discs, should be considered. Capillary forces depend on the interaction of the 
liquid and the capillary and also on the size of the capillary, i.e. on pore size, in our case. The 
surface tension of water is 72 mJ/m2 and that of PLA is around 40 mJ/m2 [133–135]. 
Accordingly, water does not wet PLA fibers and cannot penetrate into the devices easily. 
Compression obviously changed the pore structure of the device, which decreases capillary 
forces and helps penetration. As an effect of changing morphology and penetration, we may 
expect faster release of the drug from the disk than from the fiber mat. 
5.2.5. Drug diffusion study 
The release of the drug incorporated into the devices prepared from electrospun fibers is a 
complex process and depends on several factors. As the results of the XRD measurements and 
the SEM micrographs showed, the drug, MZ in this case, is incorporated into the devices in 
various forms: as precipitated crystals within and among the fibers and as dissolved molecules 
in PLA. The dissolution of these forms must be different. The PBS solution must penetrate the 
device, dissolve the crystals and diffuse out into the surrounding medium. On the other hand, 
dissolved MZ must diffuse out of the PLA fibers into the surrounding medium. The solubility 
Device 
Drug content 
(m/m%) 
Contact angle (°) after time (min) 
0 10 20 
MZ pastille 100 32.5  1.8 – – 
Fiber mat 
0 125.3  3.8 123.2  4.0 121.4  0.8 
12.2 110.8  3.1 104.6  5.3 96.0  8.9 
25.7 117.3  7.2 112.3  9.5 105.8  12.2 
Disk 
0 62.5  1.6 48.7  0.5 – 
12.2 66.9  1.4 46.4  0.3 – 
25.7 64.3  0.5 47.0  0.2 – 
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of MZ is small in PLA, and diffusion is driven by concentration difference, which is also small 
or even negative due to the large drug concentration of the surrounding solution because of the 
dissolution of the crystals. Consequently, the main factor determining the dissolution of MZ 
from the devices, i.e. drug release, is the penetration and flow of the PBS solution. This is 
different for the two devices, mats and disks, thus dissimilar drug release is expected from them. 
The time dependence of dissolution is presented in Figure 13 for the fiber mats and the disks 
at two different MZ concentrations. In view of the observations presented, some of the results 
were expected. Compressed disks release the drug much faster than fiber mats because of the 
larger and faster penetration of the aqueous medium into the pores of the device. However, the 
fact that dissolution is independent of the initial concentration of MZ in the device is somewhat 
surprising. The fast penetration and dissolution of MZ in the PBS solution can result in the 
independence of concentration. The diffusion of the liquid, which contains the dissolved drug, 
into the surrounding medium may be the rate-determining step of dissolution in this case. 
In the case of the fiber mats, the rate of dissolution depends on concentration, however, not 
as expected, i.e. higher rate at larger concentration, but in the opposite way. The slower release 
of the drug from the mats can be easily understood, if we consider the difference in the 
penetration of the aqueous medium. The effect of concentration, on the other hand, is difficult 
to explain. Obviously, the dissolution of the drug in the PBS solution and its diffusion into the 
surrounding medium are the rate-determining steps in this case. However, the presence of the 
drug did not influence diffusion rate much, thus dissolution must be dissimilar at the two 
concentrations of MZ. The larger drug concentration probably results in larger precipitated 
crystals, which leads to slower dissolution and release. 
The rate of dissolution can be estimated from the data presented in Figure 13. According to 
this evaluation, plateau concentrations are reached after 24 hours for the disks, and after 48 or 
96 hours for the fiber mats. However, time dependence can be evaluated quantitatively if 
appropriate functions are fitted to the experimental data. 
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Figure 13. Dissolution of metronidazole from fiber mats and disks. Effect of drug content. Symbols: (,) Fiber mats, (,) 
Disks; empty symbols: 12.2 m/m% MZ, full symbol: 25.7 m/m% MZ. 
The dissolution and the diffusion of the drug are determined by Fick's laws. Fick's equations 
can be solved numerically, or they can be expressed analytically using simplifications [136]. 
Two main approaches are used in practice, those describing the first part of the function plotting 
experimental results as the function of the square root of time, or those which use an exponential 
function. This approach gives a more accurate estimate at long times and it allows the estimation 
of the overall rate of dissolution and the maximum amount of dissolved material at infinite time 
(if the shape and structure of the device do not change, e.g.: fiber degradation). We followed 
the latter approach and fitted the function of Eq. 1 to the experimental results: 
 
(1) 
where Mt and M∞ are the dissolved amount of drug at time t and at infinite time, respectively, 
and a is the overall rate of dissolution. The parameters calculated from the fitting are collected 
in Table 5. 
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Table 5 Parameters characterizing the kinetics of dissolution determined by fitting Eq. 1 to the experimental results. 
Drug content 
(m/m%) 
Form a (1/h) M (%) R
2 
12.2 mat 0.233 81.9 0.8855 
25.7 mat 0.051 71.8 0.9634 
12.2 disk 0.581 89.4 0.9449 
25.7 disk 0.556 89.1 0.9650 
Results presented in Table 5 confirm our qualitative evaluation and show that dissolution is 
much faster from the disk than from the fiber mat (see parameter a). It also confirms the 
composition dependence observed. The comparison of the predicted amount of drug dissolved 
at infinite time (M∞) indicates that a considerable amount of drug, 10-30% remains in the 
devices after the dissolution experiment even in the case of the disks. Moreover, a closer 
comparison of the fitted lines and the measured values indicates that dissolution cannot be 
described with a single process; it consists of at least two steps, a rapid one at the beginning of 
the experiment and another one proceeding at a slower rate. This two-step process is 
demonstrated especially well by the results obtained on the fiber mat, containing 25.7 m/m% 
MZ. The two steps demonstrated by the blue broken line in the figure might be explained by 
the dissolution of the different forms of the drug; crystals located among the fibers dissolve 
much faster than dissolved MZ or crystals precipitated within the fibers. The different rates 
allow the regulation of the amount of the drug as a function of time and also the active lifetime 
of the device. Controlling the form of the drug in the device and the rate of water diffusion into 
the electrospun porous fiber network might be an efficient strategy to control drug release 
[137,138]. 
5.2.6. Antimicrobial effectiveness 
Disks were included in the microbiological study, as uniform shape, weight and thickness 
could not have been achieved with the fiber mats. The delivery systems evaluated contained 
12.2 and 25.7 m/m% MZ. Five different bacterial strains were used in this investigation: E. 
corrodens, P. intermedia, P. micra, F. nucleatum, and A. actinomycetemcomitans. 
The results of the microbiological study are presented in Figure 14. The duration of the 
antimicrobial effect is apparently independent of concentration; it is the same for disks with 
12.2 and 25.7 m/m% MZ content in most cases. A one-day difference appeared in growth 
inhibition for P. micra at 12.2 and 25.7 m/m% MZ contents. In the other cases, disks with a 
larger MZ content provided slightly larger inhibition zones than systems containing less drug 
on most days. Bacterial growth inhibition is shorter, only 2—3 days for A. 
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actinomycetemcomitans, E. corrodens and P. micra, while the growth of F. nucleatum and P. 
intermedia was affected for a longer time, for 13 days. 
 
Figure 14. Inhibition of the growth of anaerobic pathogen bacteria. Time is shown in days. 
The results of our measurements agree well with those published in the literature, suggesting 
that F. nucleatum and P. intermedia are more susceptible to MZ than A. 
actinomycetemcomitans, E. corrodens and P. micra, which may be completely resistant or 
minimally sensitive to the antimicrobial drug used. The diameter of the inhibition zone 
increases slightly with increasing MZ concentration, probably because of longer diffusion paths 
resulting in enhanced inhibition. The differences in the diameter of the inhibition zone are more 
pronounced for strains with larger susceptibility to MZ and they increase with time as well. 
Inhibition was observed in the growth of susceptible bacteria for as long as almost two weeks, 
indicating that our devices can be efficient for a long time. This fact, however, needs some 
consideration, because the dissolution study indicated that most of the drug is released from the 
disks in 24 hours. The contradiction might be explained by the difference in the conditions, but 
also in the presence of MZ located within the polymer in the form of dissolved molecules or 
precipitated crystals. The diffusion, thus the release rate of MZ is much slower in this latter 
case than for the drug located among the fibers in crystal form. A slower rate leads to prolonged 
inhibition times, which could result in greater patient compliance and better results of the 
periodontitis treatment. 
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5.2.7. Summary of formulated nanofiber systems 
In the second part of my work, an electrospun nanofibrous drug delivery system was created. 
12.2 and 25.7 m/m% of MZ was incorporated. The delivery systems were further modified by 
applying pressure and, therefore, made into disks. Subsequent to the investigation of native 
fibers and compressed disks containing different amounts of MZ, the following conclusions 
were obtained: 
• SEM investigations indicated that the compression process has not altered the fibers 
individually, but it has changed the capillary structure of the devices. Moreover, 
traces of MZ crystals among the fibers can be seen in the microscopic images. 
• Results of XRD measurements confirmed that the majority of MZ is in crystalline 
form in both native fibers and compressed disks and PLA has a semi-crystalline 
structure. XRD diffractograms of devices after in vitro drug diffusion measurements 
shows traces of leftover MZ, which may refer to dissolved and crystallized MZ inside 
the filaments or MZ crystals which are inaccessible for the dissolution medium 
because of poor water penetration into the delivery systems. 
• Results of wettability measurements indicated that water penetration into native 
fibers is slower than into disks. 
• In vitro drug diffusion measurements showed that compression influences the drug 
diffusion from devices. MZ was released in 24 hours from disks, in 48 hours from 
native fibers containing 12.2 m/m% MZ and in 96 hours from mats with 25.7 m/m% 
MZ. 
• Investigation of antimicrobial effectiveness of disks indicates that disks may inhibit 
the growth of bacterial strains susceptible to MZ for 13 days. 
6. SUMMARY 
The aim of my Ph.D. work was the formulation and investigation of innovative drug delivery 
systems for the treatment of periodontal disease. Novelty of this work can be summarized as 
follows: 
• The optimal composition of a local, swellable lipid-based drug delivery system was 
first described, which provides sustained release of incorporated antimicrobial agents 
and has a mucoadhesive feature. 
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• The developed lipid formulation enables incorporation of high dose of different 
antimicrobials with an easy preparation method; moreover, the diffusion of the 
hydrophilic drugs could be prolonged up to 2 weeks. 
• The synergism between the antimicrobial effect of ZnHA and MZ on 6 bacterial 
strains was proven by bacterial growth inhibition measurements. 
• The wettability and water penetration into PLA-based nanofibrous devices were 
modified by compression, therefore the drug release was also altered. 
All of the results of the measurements performed excellently illustrated the potential of the 
application of the developed lipid-based delivery system, its sustained release and high and long 
effectiveness against the growth of bacterial strains responsible for the disease. The 
effectiveness of PLA-based nanofiber disks was also shown, and results indicate that this device 
is suitable for the incorporation of antimicrobial materials. It was also proven that compression 
of nanofibers results in a device with uniform shape and size, which is convenient for the local 
treatment of periodontal disease. 
In conclusion, all of the devices described in the thesis have the potential to be used in the 
treatment of periodontal disease. 
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Abstract: Background: Periodontitis is a chronic inflammatory disease, which affects the supporting 
tissues of the teeth, and without proper treatment it may lead to tooth loss. Antibiotics - administered 
orally - have been widely used in the treatment of periodontitis. With the conventional administration 
routes, adequate drug levels cannot be reached in the periodontal pockets and oral application of antim-
icrobials could lead to side effects. Drug delivery systems containing antibiotics, administered at the 
site of infection, could possibly help eliminate pathogen bacteria and treat periodontitis.  
Objective: The aim of the recent study was to create a locally swellable, biodegradable, biocompatible, 
mucoadhesive, lipophilic drug delivery system (SDLDDS) containing antimicrobial drugs which sof-
tens at body temperature, accommodate to the shape of the periodontal pocket and can provide extended 
drug release for at least one week.  
Methods: During the formulation, thermoanalytical, consistency, wettability, swelling, degradation and 
drug release studies were applied to determine the ideal ratios of lipid bases, structure-building compo-
nents and surface active agent concentrations.  
Results and Discussion: The structure-building component cetostearyl alcohol appeared to be the most 
convenient, thanks to its wettability and mechanical properties, which led to controlled drug release. 
With the use of ideal concentrations of components (10% surfactant, 40% structure-building compo-
nent, 32 % lipid base, 15% antimicrobial agent and 3% polymer), sustained drug release can be pro-
vided up to nearly 3 weeks. 
Keywords: lipid drug delivery, sustained drug release, swelling, degradation, periodontitis, periodontal pocket, antimicrobial 
therapy. 
1. INTRODUCTION 
 Periodontitis (PD) is a chronic inflammatory disease, 
which affects the supporting tissues of the teeth, and without 
proper treatment it may lead to tooth loss [1, 2]. Periodontal 
diseases are multifactorial diseases: initiation and progres-
sion of periodontitis require the simultaneous occurrence of 
virulent periodontal pathogen microorganisms, local envi-
ronment, host susceptibility, genetic and acquired risk fac-
tors. The subgingival biofilm initiates and maintains inflam-
matory responses in the periodontal tissues and periodonto-
pathogen microorganisms also play a role directly in tissue 
damage through different virulence factors [3-5]. Inflamma-
tion is mostly caused by a wide set of microorganisms  
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(viruses, bacteria, etc.), with the most important putative 
pathogens being Gram-negative bacteria, namely Aggregati-
bacter actinomycetemcomitans, Porphyromonas gingivalis, 
Tannerella forsythia and Treponema denticola, but other 
species are also considered to be responsible for disease ini-
tiation and progression [6]. 
 The disease is characterised by the destruction of the gin-
gival tissues, the resorption of the alveolar bone, the migra-
tion of the junctional epithelium in the direction of the roots 
and the formation of a so-called periodontal pocket (PP) [2]. 
This subgingival area is ideal for the proliferation of anaero-
bic pathogen bacteria, some of which were listed above, 
which activate neutral degrading enzymes, thereby causing a 
vicious cycle [2, 6]. 
 The oral cavity and PPs have all the important features 
required to be an appropriate medium for the growth and 
maturation of a bacterial biofilm [6]. A community of bacte-
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rial cells producing a polymeric matrix in which they are 
enclosed on a surface is called a bacterial biofilm [7]. As 
there are lipids, saccharides in the nutrients and proteins and 
glycoproteins in saliva, bacteria have access to adequate 
nourishment [6]. 
 As biofilm formation and adherence to tooth surface are 
the main causes of periodontal disease, the removal of 
plaque and the eradication of microorganisms are key ele-
ments of an effective therapy [8-10]. The most common 
methods of mechanical debridement are scaling and root 
planing with some limitations, such as the inability to access 
ecological niches. The varying geometry of deep pockets, the 
irregularities of the root surface, root furcations, concavities 
and infected pocket walls are not accessible to mechanical 
removal by hand or with power-driven instruments [11]. 
Because of the imperfect removal of the bacterial biofilm 
and the high number of pathogen microorganisms present in 
the oral cavity, chances are high that the remaining microbi-
ota recolonises the subgingival area [12].  
 The infectious nature of periodontitis indicates an adjunc-
tive anti-infective chemotherapy to eradicate or reduce the 
amounts of pathogenic bacteria from ecological niches. Our 
current understanding of antimicrobial therapy requires the 
disruption of the structured biofilm by mechanical debride-
ment before antimicrobial therapy is considered [11]. 
 Antibiotics have been widely used in the treatment of PD 
and can help eliminate the oral pathogens responsible for the 
formation of the disease. However, with conventional ad-
ministration routes (e.g. per os), adequate drug levels are not 
reachable in the PPs even with high systemic concentrations. 
The oral application of high doses of antimicrobial agents 
leads to serious side effects with limited efficacy [13]. 
 As the peroral application of antimicrobial drugs is not a 
viable option, antimicrobial local drug delivery systems ap-
plied at the inflammation site could be a possibility in the 
elimination of pathogen bacteria and in the treatment of PD. 
Numerous articles demonstrated various types of local drug 
delivery systems with different active agents directed at PD 
[1, 2, 12-25]. Applicable active substances could be chlor-
hexidine, metronidazole, tetracyclines, clindamycin, oflox-
acin [2], moxifloxacin [17], amoxicillin [18] or even povi-
done iodine [26]. 
 The development of local, targeted, sustained and con-
trolled release therapeutic systems containing different active 
agents are among the hot topics of pharmaceutical research. 
Serious adverse effects of particular drugs can be prevented 
by their administration, and even a continuous effect could 
be obtained without sequential dosage and therapeutic drug 
levels can be achieved at the desired place. Different nano 
carriers [27], layered structures [22, 28], polymer matrixes 
[27, 29] and lipid systems [30, 31] may be used to achieve 
these features. 
 Sustained or controlled release of drugs can be also ob-
tained with the use of different vehicles like polymers or 
other materials capable of up-building a coherent structure 
[28, 32-34]. 
 The aim of the recent study was to create a locally swel-
lable, degradable, lipophilic drug delivery system 
(SDLDDS) containing an antimicrobial drug, which softens 
at body temperature, accommodates to the shape of the PP, is 
biodegradable, biocompatible, can provide extended drug 
release at least for one week and has a mucoadhesive feature. 
2. MATERIALS AND METHODS 
2.1. Materials 
 For the compositions Suppocire BP (SBP) pellets (Gatte-
fossé, Saint-Priest, France), Methocel E4M (Colorcon Ltd., 
Dartford, United Kingdom), Kolliphor RH40 (KP) (BASF 
ChemTrade GmbH, Ludwigshafen, Germany), amoxicillin 
(AMX) (Antibióticos de León S.L.U., León, Spain), white 
beeswax (WB), cetostearyl alcohol (CA) and metronidazole 
(MZ) (Ph. Eur. 8., Hungaropharma Plc., Budapest, Hungary) 
were used. 
 During the drug release tests, a simulated saliva solution 
was used as an acceptor phase. The composition of the solu-
tion was the following: 0.720 g/L potassium chloride, 0.600 
g/L sodium chloride, 0.030 g/L citric acid (Ph. Eur. 8., Hun-
garopharma Plc., Budapest, Hungary), 0.220 g/L calcium 
chloride dihydrate, 0.680 g/L potassium phosphate mono-
basic, 0.866 g/L sodium phosphate dodecahydrate, dibasic, 
1.500 g/L potassium bicarbonate and 0.060 g/L potassium 
thiocyanate (Ph. Eur. 8., Molar Chemicals Ltd., Halásztelek, 
Hungary) at a pH of 6.5 [35]. For wettability, swelling and 
degradation measurements purified water was used. 
 The preliminary microbiological investigations were im-
plemented with the use of a test bacterium, Streptococcus 
mutans (ATCC
®
 55677
™
), a facultatively anaerobic, oral 
streptococcus. Bacterial suspensions were made in 0.9% 
NaCl solution. Columbia agar plates with 5% of horse blood 
were used as culture media. 
2.2. Composition of the Local Drug Delivery Systems 
 Five main components were used to create the delivery 
systems. A lipophilic component SBP was chosen as the 
lipid base and CA or WB was used as a structure-building 
component. All of the lipid components can be safely used 
on mucosae, where the SBP can soften at body temperature. 
Each structure-building component was used in four differ-
ent concentrations, from which the best was chosen accord-
ing to the results of different measurements. 
 KP was used as a surface active agent, which helps the 
wetting of the formulation in the PP and thus, promotes its 
swelling and degradation. Different concentrations were ap-
plied to decide which is the most suitable for the delivery 
system. 
 Methocel E4M (HPMC) was used as a swelling and 
bioadhesive agent. 
 AMX or MZ, which are often used in PD treatment, were 
incorporated into the vehicles. 
 All of the formulations were created by melting. At first, 
the two lipophilic components and the surfactant were melted 
together at 70 °C on a hot plate (IKA-WERKE RCT B, ETS-
D4, IKA Werke GmbH & Co. KG, Staufen im Breisgau, 
Germany), then the polymer was added and homogenized with 
an overhead stirrer at 50 RPM (Digital Overhead Stirrer - 
DLH, VELP Scientifica, Usmate Velate, Italy). The antimi-
crobial agent was only added right before moulding to avoid 
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its possible thermal decomposition. Delivery systems were 
created by moulding the melted formulations into a round 
shaped mould 1.5 mm in thickness and 9 mm in diameter. 
 The optimal ratio of the ingredients was determined by 
various methods described below. Before any measurement, 
the formulations were kept at room temperature in a desicca-
tor for at least 24 h to reach complete solidification. 
 The compositions of different formulations examined 
during our study can be found in Table 1. The course of the 
investigations is shown in Fig. (1). 
2.3. Differential Scanning Calorimetry (DSC) Measure-
ments 
 DSC measurements were used to determine the softening 
temperature and the effect of the structure-building compo-
nent on the melting point and the structure. All of the meas-
urements were done with a Mettler-Toledo DSC 821
e
 in-
strument in argon atmosphere (100 mL/min) between + 10 
and 100 °C raising the temperature by 5 °C per minute. 10 
mg of the samples were placed into 40-?L aluminium pans. 
The pans were sealed and holed on top. 
 
Table 1. The composition of formulations analysed with different methods. 
Concentration of the Components (%) 
Structure-building 
Component 
Lipid Base Surfactant Polymer Antimicrobials Measurements 
WB CA SBP KP Methocel E4M MZ AMX 
10 0 85 5 0 0 0 
10 0 80 10 0 0 0 
10 0 75 15 0 0 0 
10 0 70 20 0 0 0 
0 5 90 5 0 0 0 
0 5 85 10 0 0 0 
0 5 80 15 0 0 0 
0 5 75 20 0 0 0 
20 0 67 10 3 0 0 
40 0 47 10 3 0 0 
60 0 27 10 3 0 0 
0 20 67 10 3 0 0 
0 40 47 10 3 0 0 
DSC, 
Wettability, 
Penetrometry 
0 60 27 10 3 0 0 
20 0 67 10 3 0 0 
40 0 47 10 3 0 0 
60 0 27 10 3 0 0 
0 20 67 10 3 0 0 
0 40 47 10 3 0 0 
Swelling and degradation 
0 60 27 10 3 0 0 
20 0 57 10 3 10 0 
40 0 37 10 3 10 0 
60 0 17 10 3 10 0 
0 20 57 10 3 10 0 
0 40 37 10 3 10 0 
0 60 17 10 3 10 0 
0 20 57 10 3 0 10 
0 40 37 10 3 0 10 
Drug release study 
0 60 17 10 3 0 10 
0 40 42 10 3 0 5 
0 40 37 10 3 0 10 
Preliminary microbiological 
study 
0 40 32 10 3 0 15 
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Fig. (1). Flowchart showing the course of the investigations. 
2.4. Wettability of the Delivery Systems 
 The wettability of the formulations was studied with an 
OCA Contact Angle System (Dataphysics OCA 20, Data-
physics Inc., GmbH, Germany). As a flat surface is needed 
for optical contact angle measurements to be carried out, 
microscopic slides were covered with the melted formula-
tions (without active ingredients). After moulding, they were 
stored at room temperature in a desiccator for 24 h. The de-
gree of wetting was determined by measuring the contact 
angle: 10 μL of water from a calibrated syringe was dripped 
on the surface of the formulations moulded onto the micro-
scopic slides, and the contact angle of the water droplets and 
the formulations was measured by computer software. 
2.5. Determination of Consistency by Penetrometry 
 The consistency of the different formulations was deter-
mined with a penetrometer (07/2008:20909, 2.9.9, 2.9.9.-1,-
3., Ph. Eur. 8) by measuring the penetration depth of a pene-
trating object into the test samples. Melted samples were 
poured into Petri dishes, and they were stored at room tem-
perature for 24 h in a desiccator to reach the total solidifica-
tion. Five parallel measurements were carried out with each 
sample at room temperature. The penetration depth was 
measured for one minute. The penetration depth directly 
refers to the consistency of the samples. 
2.6. Swelling and Degradation 
 The water absorption capacity of the formulations was 
determined gravimetrically in order to examine the effects of 
the incorporated polymer on the swelling and degradation 
properties of the delivery systems. At first, the formulations 
were weighed with an analytical scale then were immersed 
into 10 mL of distilled water and were thermostated at 37°C 
for various periods of time (1, 1.5, 2, 3, 4, 5, 6, 7 and 14 
days). After the defined time periods, they were weighed 
again. After the second measurement, the formulations were 
held at room temperature until they totally dried out, and 
they were weighed again for a third time. With the results, 
the absorption capacity and the swelling related degradation 
could be determined. 
2.7. Drug Release Study 
 The in vitro drug release profiles of the formulations 
were determined. The compositions were weighed with an 
analytical scale and put in 5-cm-long dialysis tubes (Spec-
tra/Por
®
 Standard RC tubing, MWCO: 12-14 kD) and sealed 
with closures. The tubes containing the formulations were 
placed in 50 mL of acceptor phase thermostated at 37 °C. As 
an acceptor phase, a simulated saliva solution was used. 
Drug release was investigated for 48 h and 3 parallel meas-
urements were carried out. 5 mL of samples were taken (at 
0.5, 1, 4, 8, 12, 24, 36, 48 hours) and were replaced with 5 
mL of acceptor phase. The released drug, AMX and MZ, 
was quantified by UV spectrophotometry (Helios ? Ther-
mospectronic UV-spectrophotometer v4.55, Unicam: 
Thermo Fisher Scientific, Waltham, MA) at 273 and 318 nm, 
respectively. 
2.8. Investigation of Sustained Antimicrobial Effect: Pre-
liminary Study 
 A preliminary microbiological study was conducted in 
order to measure the antibacterial effectiveness of the devel-
oped formulations. As a typical oral bacterium, Streptococ-
cus mutans control strain was used. A 0.5 McFarland stan-
dard concentration bacterial suspension was made with 0.9% 
NaCl solution (in suspension it is equivalent to approxi-
mately 1.5?108 colony forming units/mL). The suspension 
was spread onto a horse blood agar plate, then formulations 
containing 5, 10 and 15 m/m % of AMX were placed on it. 
After 24 hours of incubation in 5% CO2 atmosphere, the di-
ameter of the inhibition zones was measured. The formula-
tions were then put on a new horse blood agar plate, also 
inoculated with 0.5 McFarland standard concentration 
freshly made bacterial suspension of Streptococcus mutans. 
The plates were then put in 5% CO2 atmosphere for 24 
hours. This was repeated until no inhibition zone could be 
detected. 
2.9. Statistical Analysis 
 The results of the drug release measurements were ana-
lysed statistically with GraphPad Prism version 5 software, 
using two-way ANOVA analysis with Bonferroni post-tests. 
A level of p?0.05 was considered significant, p?0.01, very 
significant, and p?0.001 highly significant. 
3. RESULTS AND DISCUSSION 
3.1. Differential Scanning Calorimetry (DSC) Measure-
ments 
 DSC was used to determine the concentration of the 
structure-building component and the softening temperature 
of the formulations. 
 One of the structure-building components is white bees-
wax, which is natural beeswax but chemically bleached. It 
consists of esters of C24 to C36 straight-chain alcohols and 
straight-chain acids. It is used in creams, oils, ointments to 
Formulation and Investigation of a Lipid Based Delivery System Current Drug Delivery, 2018, Vol. 15, No. 0    5 
increase consistency and in emulsions as a stabilizer. Ac-
cording to the literature, its melting point is between 60-67 
°C [36]. In our investigation, DSC measurements show an 
endothermic peak at 64.45 °C (Fig. 2). 
 The other type of structure-building component is ce-
tostearyl alcohol, which is a mixture of solid alcohols and 
consists of mainly stearyl and cetyl alcohols. It is mostly 
used in semisolids as a surfactant, a co-surfactant or as a 
viscosity increasing agent. In oral dosage forms it may slow 
the dissolution. The specific melting range of the substance 
is between 48-56 °C [36]. According to our DSC measure-
ments, it is 56.61 °C (Fig. 2).  
 Kolliphor RH40 is a polyoxyethylene 40 castor oil de-
rivative. It can be used as an emulsifying or wetting agent. 
According to the literature [36] and the DSC measurements, 
it has a congealing temperature at 16-26 °C, and a melting 
point approximately at 30 °C (Fig. 2). 
 Suppocire BP was used as the lipophilic base of the sys-
tems. It has a melting range between 36-37 °C and a hy-
droxyl value between 30 and 50. Mostly, it is used as a base 
for suppositories [36]. According to our measurements, it has 
a melting point at 39.08 °C (Fig. 2). 
 Our results show that the softening temperature of the 
systems meets our expectations as all of the systems soften 
partially between 34-36 °C, which is slightly lower than the 
average body temperature in the oral cavity (Fig. 2), result-
ing in adaptation to the geometry of PPs. 
 Firstly, we evaluated how the concentration of the sur-
face active agent affects the melting point of the composi-
tions. The concentration of the structure-building component 
was fixed (WB at 10 m/m % or CA at 5 m/m %). The effect 
of the increasing quantity of the surface active agent (from 5 
m/m % to 20 m/m %) on the melting point was examined. 
The graphs (Figs. 2 and 3) clearly show that the specific en-
dothermic peak at the melting point of the structure-building 
component (WB: 64.45 °C, CA: 56.61 °C) cannot be seen, 
which means that in this concentration range the structure-
building components are incorporated homogeneously into 
the structure instead of the formation of a separated crystal-
line structure. Besides this, the 37°C melting point of SBP 
decreases and the sharp peak at 37°C broadens in the direc-
tion of lower temperatures, but the melting point stays above 
35°C. 
 Following this, the effect of the concentration of the 
structure-building component on the thermal behaviour of 
the formulations was evaluated. In this case, the concentra-
tion of the surface active agent was held at the mean value of 
10 m/m %, while the concentration of the structure-building 
component was changed from 5 m/m % (CA) or 10 m/m % 
(WB) to 20, 40 and 60 m/m %. It can be seen clearly that 
with the increasing concentration of the structure-building 
component, another peak appears above the temperature of 
40 °C, which corresponds to the melting point of waxes, but 
it is lower than the melting point of the pure material. The 
peak at the melting point of SBP shifted to lower tempera-
tures when the concentration of the structure-building com-
ponent was increased to 20 m/m % and shifted to higher 
temperatures when it was changed to 40 or 60 m/m %. (Figs. 
4 and 5). 
 
Fig. (2). DSC curves of pure Suppocire BP, white beeswax and 
Kolliphor RH40 and the compositions containing 10 m/m % white 
beeswax and 5, 10, 15 and 20 m/m % of surface active agent. 
 
 
Fig. (3). DSC curves of pure Suppocire BP, cetostearyl alcohol, 
Kolliphor RH40 and the compositions containing 5 m/m % ce-
tostearyl alcohol, 5, 10, 15 and 20 m/m % of surface active agent. 
 
 The DSC results (Figs. 4 and 5) clearly show that for for-
mulations containing 20 m/m % of structure-building compo-
nent there is no separate peak of the base and the structure 
building component, which will result in total melting at body 
temperature and sustained drug release probably cannot be 
reached thanks to the disintegration of the melted formulation. 
 The compositions containing 40 and 60 m/m % of the 
structure-building component show different results. The 
peaks of the structure-building component and the lipid base 
are separate, thus there is a compound with a lower melting 
point and another with a higher one (Figs. 4 and 5) From this 
it can be concluded that the system has a part which will 
melt or soften at body temperature, and another part which 
will give a structure to the system even at body temperature, 
thereby hindering disintegration and fast degradation. 
3.2. Wettability of the Delivery Systems 
 As the systems are mostly hydrophobic, a surface active 
agent is needed to help the wetting of the  delivery  systems  
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Fig. (4). DSC curves of pure Suppocire BP, white beeswax and 
Kolliphor RH40 and the compositions containing different concen-
trations (20, 40 and 60 m/m %) of structure-building component 
(white beeswax). 
 
 
Fig. (5). DSC curves of pure Suppocire BP, cetostearyl alcohol and 
Kolliphor RH40 and the compositions containing different concen-
trations (20, 40 and 60 m/m %) of structure-building component 
(cetostearyl alcohol). 
 
with exudates in PPs, which is critical to the swelling of the 
preparations and consequently to drug release. Good wetting 
contributes to the degradation and elimination of the systems 
from the PP. An optical contact angle measurement system 
was used to determine the wettability of our systems. 
 First, we evaluated the effect of various concentrations of 
the surface active agent (5, 10, 15 and 20 m/m %), then we 
measured the effect of the structure-building components 
with constant surfactant concentrations. 
 In case of beeswax and the varying concentrations of sur-
face active agent, the higher concentrations of surfactant de-
creased the contact angle, which means the wetting properties 
of the delivery systems became better. There is no remarkable 
difference between the preparations containing 10, 15 and 20 
m/m % of surface active agent (Table 2). Based on the results 
of formulations containing WB, the best is the 10 m/m % con-
centration of surface active agent as the same wettability can 
be reached with higher amounts of wetting agent. 
 The evaluation of the results of the drug delivery systems 
containing CA as a structure-building component showed 
that the formulation with the best wettability was the one 
with 20 m/m % of surfactant (Table 2). Contact angles had a 
max. value at 15 m/m % of surface active agent, but the dif-
ferences between the various compositions were not remark-
able so the 10 m/m % of surfactant was chosen. All of the 
formulations made with CA (except the one with the 15 m/m 
% of surfactant) had better wettability than the preparations 
containing WB. 
 The effect of the different concentrations of the structure-
building component on the wettability of the preparations 
was measured. The concentration of the wetting agent was 
held at a 10 m/m % value (Table 3). 
 Increasing concentrations of WB increased wettability as 
the contact angle was smaller. The same is not applicable to 
the formulations containing CA. The contact angle increases 
with increasing the CA concentration (Table 3). 
3.3. Determination of Consistency by Penetrometry 
 The consistency of the formulations was measured by 
penetrometry. The penetration depth of a penetrating object 
into a test sample was measured. From penetration depth 
consistency can be calculated or it directly refers to the con-
sistency of the samples. The effect of the surface active agent 
and the structure-building component on consistency was 
evaluated. 
Table 2. Average and SD of contact angles of compositions, made with white beeswax or cetostearyl alcohol, containing different 
concentrations (5, 10, 15 and 20 m/m %) of surface active agent. 
Contact angle (°) 
Concentration of KP (%) 
WB CA 
 Average SD Average SD 
5 94.63 1.63 66.81 3.20 
10 98.04 4.10 75.44 8.72 
15 98.33 1.32 102.24 1.63 
20 100.86 0.65 58.29 6.12 
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 Formulations made with CA were harder as penetration 
into the test objects was smaller. The concentration of the 
surface active agent had a small effect on penetration depth 
and consistency. The increasing concentration of KP caused 
deeper penetration into the penetrating objects except for the 
preparations made with CA containing 15 m/m % and 20 
m/m % of KP, where the penetration depth was 0.03 mm 
deeper when measuring the system with a smaller quantity of 
surface active agent (Table 4). 
 As the surfactant concentration had not influenced the 
penetration depth remarkably, in accordance with the DSC 
and wettability results the formulations with 10 m/m % of 
surface active agent was chosen to carry out the further in-
vestigations. 
 The penetration depth into preparations made with differ-
ent concentrations of structure-building component was also 
evaluated. The concentration of the surface active agent was 
held at a constant 10 m/m % value. The increasing quantity 
of the structure-building component in case of both WB and 
CA made the formulations harder and the penetration depth 
shallower. CA had a greater impact on penetration depth and 
consistency than WB because 40 and 60 m/m % concentra-
tions showed a higher decrease in penetration depth (Table 
5). 
 The formulations containing CA have better wettability 
and solidity, which may influence not only the application of 
the system but also drug release. 
3.4. Swelling and Degradation 
 The swelling and degradation properties of formulations 
containing 20, 40 and 60 m/m % of CA were measured gra-
vimetrically to determine whether the preparations are able 
to absorb water, swell and degrade. Degradation is necessary 
as the systems are aimed to be biodegradable and to be 
eliminated from the subgingival area. 
 The formulations containing 20 m/m % of structure-
building component fell apart on the first day of measure-
ment. In light of this, the results connected to 20 m/m % of 
CA are not shown in the figures. 
 Fig. (6) shows the swelling ratio of the formulations con-
taining 40 and 60 m/m % of CA. 
 Swelling ratio was calculated as follows: 
           (1) 
where ms is the mass of the formulations after immersed in 
water for the specified time and md is the mass of the dried 
formulations. 
 The results show that the preparations containing 40 m/m 
% of structure-building component can absorb more water as 
they are not as hard as the formulations containing 60 m/m 
% of CA (Fig. 6). 
 Swelling lasts for four days, then the swelling ratio re-
mains on the same level. This may happen because a balance 
is formed between swelling and degradation (Fig. 6). 
Table 3. Average and SD of contact angles of compositions containing different concentrations of the structure-building compo-
nents (white beeswax or cetostearyl alcohol) compared to compositions with a lower quantity of structure-building com-
ponent. 
Contact Angle (°) 
WB CA 
Concentration of the Structure-building 
Component (%) 
Average SD Average SD 
20 91.80 7.53 46.60 7.19 
40 76.27 11.12 60.95 4.15 
60 74.30 7.65 69.16 1.71 
 
Table 4. Average and SD of penetration into compositions, made with white beeswax or cetostearyl alcohol, containing different 
concentrations (5, 10, 15 and 20 m/m %) of surface active agent. 
Penetration Depth (mm) 
WB CA Concentration of KP (%) 
Average SD Average SD 
5 5.63 0.25 4.34 0.07 
10 5.76 0.34 4.54 0.11 
15 5.79 0.27 4.87 0.20 
20 6.54 0.27 4.84 0.26 
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Fig. (6). Swelling ratio of compositions containing 40 and 60 m/m 
% of cetostearyl alcohol. ? 40 m/m %, ? 60 m/m % of cetostearyl 
alcohol. 
 
 Degradation (%) was calculated from the following equa-
tion: 
          (2) 
where mo is the mass of the original formulations and md is 
the mass of the dried formulation after the swelling and deg-
radation measurements. 
 Degradation properties show no remarkable differences 
between the two concentrations. Similarly to swelling, the 
increase of degradation stops on the fourth day as a possible 
result of a balance between swelling and degradation (Fig. 7). 
3.5. Drug Release Study 
 Drug release measurements were performed to investi-
gate the possibility of achieving the sustained release of ac-
tive agents by using increasing concentrations of the struc-
ture-building component. Both of the structure-building 
agents were tested. The drug release of two different antimi-
crobials (amoxicillin and metronidazole) was evaluated from 
the compositions. 
 AMX is a semi-synthetic penicillin derivative, with a 
broad spectrum of antibiotic activity against aerobic or an-
aerobic Gram-positive and Gram-negative bacteria [18, 37]. 
 
Fig. (7). Degradation of compositions containing 40 and 60 m/m % 
of cetostearyl alcohol. ? 40 m/m %, ? 60 m/m % cetostearyl alco-
hol. 
 
 MZ is an antibacterial agent, belonging to the nitroimida-
zole group. It is known to be effective against numerous bac-
teria and protozoa, including anaerobes [2, 38]. 
 MZ and AMX are also used in the therapy of periodontal 
disease as an adjunct to the mechanical debridement (scaling, 
root planing) locally or systematically [39].  
 Six different compositions were measured and with every 
composition 3 parallel measurements were carried out. The 
release of MZ was investigated from systems made with WB 
and CA. AMX release was only tested for preparations with 
CA due to the results of MZ release. The formulations con-
tained: SBP, Methocel E4M, KP, 20, 40 and 60 m/m % of 
WB or CA, 10 m/m % of AMX or MZ. 
 The results of the evaluation of MZ release from formu-
lations containing 20, 40 and 60 m/m % of WB showed large 
SD values. This may be due to the fact that the compositions 
fell apart during the drug release tests. It can be concluded 
that WB is unsuitable for providing the sustained release of 
antimicrobial agents, so because of this AMX release was 
measured only from formulations made with CA. 
 The results show that, with increasing concentrations of 
CA, it is possible to prolong the MZ release from the formu-
lations (Fig. 8). Fig. (8) shows  that  formulations  containing  
Table 5. Average and SD of penetration into compositions containing different concentrations of the structure-building compo-
nents (white beeswax or cetostearyl alcohol) compared to compositions with a lower quantity of structure-building com-
ponent. 
Penetration Depth (mm) 
WB CA 
Concentration of the Structure-building 
Component (%) 
Average SD Average SD 
20 4.85 0.12 4.95 0.26 
40 4.35 0.15 3.17 0.27 
60 3.60 0.23 1.87 0.09 
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Fig. (8). Release of metronidazole from formulations containing 
different concentrations (20, 40 and 60 m/m %) of cetostearyl alco-
hol. ? 20 m/m %, ? 40 m/m %, ? 60 m/m % cetostearyl alcohol. 
Drug release from compositions containing 40 and 60 m/m % ce-
tostearyl alcohol shows highly significant difference (***) com-
pared to formulations with 20 m/m % cetostearyl alcohol at 4, 8 and 
12 hours. 
 
20 m/m % of CA have a faster drug release than the formula-
tions made with 40 or 60 m/m % of CA, which can be ex-
plained by the faster degradation of formulations containing 
20 m/m % CA during the drug release measurements. There 
is no significant difference between the systems containing 
40 or 60 m/m % of structure-building components. 
 AMX release from formulations made with CA was simi-
lar to the release of MZ as it was possible to sustain the AMX 
release. Another similarity to MZ release is that there is no 
significant difference between the release of AMX from for-
mulations made with 40 m/m % and 60 m/m % CA (Fig. 9). 
 The drug release mechanism can be characterized with 
the following equation: 
            (3) 
where  is the fraction of drug released, k is the kinetic 
constant and n is the release exponent describing the mecha-
nism of the release [40]. 
 
Fig. (9). Release of amoxicillin from formulations containing dif-
ferent concentrations (20, 40 and 60 m/m %) of cetostearyl alcohol. 
? 20 m/m %, ? 40 m/m %, ? 60 m/m % cetostearyl alcohol. Drug 
release from compositions containing 40 m/m % cetostearyl alcohol 
shows significant difference at (*) at 8 hours compared to formula-
tions with 20 m/m % cetostearyl alcohol. The drug release from 
compositions containing 60 m/m % cetostearyl alcohol also shows 
significant difference (*) at 8 and 12 hours compared to formula-
tions with 20 m/m % cetostearyl alcohol. 
 
 These values were determined from the equation of drug 
release curves (Table 6). 
3.6. Investigation of Sustained Antimicrobial Effect: Pre-
liminary Study 
 A preliminary microbiological study was made to inves-
tigate the sustained microbiological activity of our formula-
tions containing 5, 10 and 15 m/m % of AMX. The results 
are in Table 7. The diameter of the inhibition zone was 
measured in mm and it is the average of two perpendicular 
diameters. The averages were rounded to integer numbers. 
 AMX containing systems inhibited bacterial growth for 8 
to 21 days. 
 With 5 m/m % of AMX incorporated into the systems, 
growth inhibition lasted for 8 days. 10 m/m % of AMX caused 
a 10-day growth inhibition, while the 15 m/m % one lasted for 
21 days. The inhibition zone of the 15 m/m % AMX contain-
Table 6. Release exponent (n) and kinetic constant (k) at different structure-building component concentrations of formulations 
containing amoxicillin or metronidazole and the R
2
 values of the fitted curves. 
Active Ingredient 
Structure-building Component  
Concentration (m/m %) 
n k R
2
 
20 0.5560 15.169 0,9598 
40 0.8717 4.5846 0,9853 MZ 
60 0.8808 4.4657 0,9866 
20 0,8503 5,4502 0,9416 
40 0,9264 3,1313 0,9721 AMX 
60 0,8457 4,1243 0,9955 
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ing formulation could not be measured after 24 h as there was 
no detectable growth of the bacteria in the Petri dish. The larg-
est measurable inhibition zone was 60 mm in diameter and 
was smaller and smaller day by day (Table 7). 
 The shrinking zones are the signs of the decreasing con-
centrations of the active ingredient in the formulations as the 
systems were put on a new plate in every 24 h. 
 During the microbiological evaluation all of the formula-
tions absorbed water, swelled. Water absorption and swelling 
are necessary for drug release. 
 The prolonged antibacterial effect means that our deliv-
ery system is ready to sustain the AMX release (Table 7). 
CONCLUSION 
 By developing lipid formulations, anhydrous drug deliv-
ery systems could be prepared which soften at body tempera-
ture, therefore they fit the geometry of the periodontal pock-
ets. Wettability is provided by the added surface active 
agent, while the softening at body temperature is due to the 
low melting point of the lipid components (35-37 °C). Sus-
tained drug release is supported by the structure-building 
components. 
 According to the wettability measurements, the 10 m/m 
% Kolliphor RH40 concentration is optimal. The type and 
the concentration of the structure-building component highly 
influence hardness and - under 40 m/m % - drug release. The 
results of penetrometry, the swelling, degradation and drug 
release measurements indicate that the optimal structure-
building component is CA in 40 m/m %. In this composition 
the formula softens at body temperature and prolonged drug 
release can be ensured as well. Sustained drug release was 
also confirmed with a preliminary antimicrobial test. 
 In our work, we formulated a subgingival, swellable, 
biodegradable drug delivery system, which could provide 
sustained antimicrobial activity up to almost 3 weeks. 
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Abstract: Background: Despite being a highly prevalent disease and a possible contributor to adult
tooth loss, periodontitis possesses no well-established therapy. The aim of the recent study was the
development and evaluation of a mucoadhesive monophase lipid formulation for the sustained
local delivery of amoxicillin, metronidazole, and/or zinc hyaluronate or gluconate. Methods:
To investigate our formulations, differential scanning calorimetry, X-ray diffraction, swelling, erosion,
mucoadhesivity, drug release, and antimicrobial measurements were performed. Results: Differential
scanning calorimetry (DSC) and X-ray diffraction (XRD) results show that the loaded drugs are in a
suspended form, the softening of the formulations starts at body temperature, but a part remains
solid, providing sustained release. Swelling of the lipid compositions is affected by the hydrophilic
components, their concentration, and the strength of the coherent lipid structure, while their
erosion is impacted by the emulsification of melted lipid components. Conclusions: Results of
drug release and antimicrobial effectiveness measurements show that a sustained release may be
obtained. Amoxicillin had higher effectiveness against oral pathogens than metronidazole or zinc
hyaluronate alone, but the combination of the two latter could provide similar effectiveness to
amoxicillin. The applied mucoadhesive polymer may affect adhesivity, drug release through the
swelling mechanism, and antimicrobial effect as well.
Keywords: periodontitis; lipid drug delivery; zinc hyaluronate; amoxicillin; metronidazole
1. Introduction
The plaque-induced forms of periodontal diseases are the most prevalent chronic inflammatory
conditions seen in humans worldwide, affecting nearly half of the adults. Periodontitis is a major
health problem reducing the quality of life. Not only does it cause tooth loss, disability, masticatory
dysfunction, poor nutritional status, and compromised speech, but it is also independently associated
with systemic chronic inflammatory diseases including atherogenic cardiovascular disease, type 2
diabetes mellitus, rheumatoid arthritis, chronic kidney disease, obesity, and chronic obstructive
pulmonary disease [1–3].
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Periodontitis is predominantly a bacterial infection involving the accumulation of different
bacteria on the non-shedding surfaces. In susceptible patients, dental plaque comprises periodontal
pathogenic microorganisms which initiate and trigger a dysfunctional inflammatory immune response,
which results in the destruction of the underlying supporting tissues. The host response to the
initiating periodontopathogens is mostly a genetically determined non-modifiable risk factor. However,
modifiable or eliminative risk factors play an important role in changing the susceptibility or resistance
of individuals to the disease. Such risk factors are smoking, poorly controlled diabetes mellitus,
obesity, stress, osteopenia, and inadequate intake of calcium and vitamin D. [1]. The most important
modifiable local risk factor is poor oral hygiene, which may initiate the infective inflammatory process
in periodontal tissues.
Treatment of periodontitis involves a fine balance of various non-surgical and surgical methods
carried out in order to reduce periodontal pocket depth, access residual plaque, initiate the regeneration
of periodontal supporting tissues and decrease the risk of disease progression. Subgingival anti-
infective therapy performed together with self-performed plaque control provides significant benefits
in clinical parameters and improvement of systemic inflammatory markers [4].
Non-surgical periodontal treatment consists of professional removal of plaque and calculus,
elimination of plaque retentive factors, oral hygiene instruction, chemical plaque control and antibiotic
medication. Treatment of teeth with tooth/site-dependent factors (e.g., the presence of plaque,
anatomic features, deep pocket, furcation involvement, intrabony defect) is less predictable and
bears an elevated risk of the progression of the breakdown of periodontal tissues [5]. Mechanical
therapy alone may have limited effect on some periodontopathogens and fail to eliminate them
in ecological niches (e.g., infected epithelial and connective tissue pocket wall, scratches left after
mechanical debridement, resorption lacunae, accessory root canal, dentinal tubules, dorsal part of the
tongue, tonsils, oral mucosa, etc.). These limitations indicate the importance of the employment of
pharmacologic agents in periodontal therapy [4].
Pharmacologic therapies are based on the administration of antimicrobials (including antiseptics
and local delivery or systemic regimen of antibiotics) and probiotics and host modulation. Systemic
antimicrobials should be applied adjunctively to mechanical non-surgical treatment—preferably in
patients with aggressive or recurrent forms of periodontitis—and may provide additional benefits in
case of very deep pockets or specific microbial infections. Systemic antimicrobial therapy is the most
effective when the mechanical disruption of the subgingival biofilm is performed during subgingival
debridement. The combination of amoxicillin and metronidazole or ciprofloxacin and metronidazole
show greater clinical effectiveness than monotherapy [4,6].
The local delivery of antimicrobial drugs may reduce the systemic adverse effects and provide
effective drug concentrations in the periodontal pockets to eliminate the pathogens from the
subgingival area [7,8]. Local application of antibiotics has been advocated for patients with localized
lesions or a limited amount of non-responding or recurrent sites [4]. In the literature, many articles
are about the development of various types of delivery systems (fibers, films, gels, strips, injectable
systems, microparticles) containing different active agents (tetracycline, doxycycline, chlorhexidine,
clindamycin, metronidazole, amoxicillin, povidone-iodine) [7,9–22].
In the last 10–15 years, lipid drug delivery received considerable attention due to advancement
in the field. Administration of lipid materials is most prevalent in solubility enhancing, lymphatic
transport targeting, and/or intestinal transport modulation aiming the increased bioavailability of
drug formulations, but creating sustained release systems, covering the bitter or bad taste of active
ingredients or protecting drug molecules susceptible to different environmental factors may also be a
purpose for the application of lipid excipients [23].
In periodontal therapy, using lipid formulations may provide the prolonged liberation of
hydrophilic antimicrobial agents, while protecting them from decomposition in hydrophilic media
and masking their unpleasant taste.
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The aim of the recent study was to develop a lipid-based formulation, which can be inserted into
the periodontal pocket, has mucoadhesive features and provides sustained delivery of antimicrobial
agents, such as amoxicillin, metronidazole and zinc derivatives (zinc hyaluronate, and zinc gluconate).
Due to the fact that the applications site possesses special qualities, the following requirements were
considered to be met by our drug delivery system: to have a softening point at body temperature to
help the adaptation of the dosage form to the shape of periodontal pockets; to be biodegradable to let
the delivery system vanish slowly from periodontal pockets as healing commences; to be biocompatible
not to trigger further inflammatory processes; and to provide sustained drug release for at least one
week. In addition to softening, the purpose of the lipid composition was to create an anhydrous
medium, which could protect the antimicrobial agents (amoxicillin) from decomposition and can have
a taste-masking effect in the case of metronidazole. This paper also aims to investigate the properties
of these delivery systems. During the development, different investigational methods were employed
in order to examine the properties of the delivery systems. The measurements carried out included
differential scanning calorimetry (DSC), X-ray diffraction (XRD), and mucoadhesion measurements,
and also drug diffusion studies and antimicrobial effectiveness investigations.
2. Materials and Methods
2.1. Materials
Suppocire BP (SBP) pellets (Gattefossé Ltd., Saint-Priest, France), Methocel E4M HPMC (Colorcon
Ltd., Dartford, United Kingdom), Kolliphor RH40 (KP) (BASF ChemTrade GmbH, Ludwigshafen,
Germany), amoxicillin (AMX) (Antibióticos de León S.L.U., León, Spain), cetostearyl alcohol (CA),
metronidazole (MZ), zinc gluconate (ZnGlu) (Ph. Eur. 8., Hungaropharma Plc., Budapest, Hungary),
and zinc hyaluronate (ZnHA) (Richter Gedeon Ltd., Budapest, Hungary) were used to create the
delivery systems.
For the mucoadhesion and drug dissolution tests, a phosphate-buffered saline (PBS) solution
was prepared by dissolving 8 g/dm3 NaCl, 0.2 g/dm3 KCl, 1.44 g/dm−3 Na2HPO4 · 2 H2O and
0.12 g/dm3 KH2PO4 (Ph. Eur. 8., Hungaropharma Plc., Budapest, Hungary) in distilled water. The pH
was adjusted to 7.4 by adding an adequate amount of 0.1 M HCl. The mucin (porcine gastric mucin
type II, Sigma-Aldrich, Saint Louis, MO, USA) was used in the form of an 8 w/w% suspension.
2.2. Composition of the Drug Delivery Systems
The exact composition of different formulations can be found in Table 1. Five main components
were used to create the delivery systems. A lipophilic component SBP was chosen as lipid base and
CA was used as a structure-building component. All of the lipid components can be safely used on
mucosae, where the SBP can soften at body temperature providing the accommodation of the dosage
form to the periodontal pocket.
Table 1. Composition of formulations 1–6. All values are given in w/w%.
Formulation No. Component 1 2 3 4 5 6
Suppocire BP 33% 33% 33% 47% 46.8% 32%
Cetostearyl alcohol 40% 40% 40% 40% 40% 40%
Kolliphor RH40 10% 10% 10% 10% 10% 10%
Methocel E4M 2% 2% 2% - - -
Metronidazole - 15% 7.5% - - 15%
Zinc hyaluronate - - - 3% 3% 3%
Amoxicillin 15% - 7.5% - - -
Zinc gluconate - - - - 0.2% -
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Cetostearyl alcohol (CA) consists of mainly stearyl and cetyl alcohols; it is a mixture of solid
alcohols, it was used to increase the softening temperature of the formulations.
KP, a polyoxyethylene 40 castor oil derivative, was used as a surface-active agent, which helps
the wetting of the formulation in the periodontal pocket; thus, it promotes its swelling and erosion.
HPMC (hydroxypropyl methylcellulose) and ZnHA were applied as gelling and mucoadhesive
components. During the erosion of the formulations, they can help to prolong the retention time
of the systems in the periodontal pockets. HPMC is often used as a mucoadhesive agent in oral
formulations such as films [24] or buccal tablets [25] to increase the residence time of the delivery
system, while ZnHA is regularly applied in topical gels to accelerate the healing of wounds of different
etiologies and to decrease the chance of a possible bacterial superinfection [26], or may be used as a
mucoadhesive agent in ophthalmic solutions to lengthen clearance and provide higher efficiency [27].
AMX or MZ, which are regularly applied orally for PD treatment, were incorporated into the
vehicles. ZnGlu was also incorporated into one of the formulations as an antimicrobial agent. Zn salts
have a known antibacterial effect, which can be useful in periodontitis treatment.
All the formulations were created by a melting and homogenation method. At first, the two
lipophilic components (cetostearyl alcohol and Suppocire BP) and the surfactant (Kolliphor RH40) were
melted together at 70 ◦C on a hot plate (IKA-WERKE RCT B, ETS-D4, IKA Werke GmbH and Co. KG,
Staufen im Breisgau, Germany), then the polymer (zinc hyaluronate or Methocel E4M) was suspended
and homogenized with an overhead stirrer at 50 RPM (Digital Overhead Stirrer–DLH, VELP Scientifica,
Usmate Velate, Italy). The antimicrobial agent(s) (amoxicillin, metronidazole, zinc gluconate) was/were
dispersed and homogenized at 50 ◦C to avoid thermal decomposition [28]. Delivery systems were
created by molding the melted formulations into round shaped silicone molds. Cylindrical drug
delivery systems were 1.5 mm in thickness and 9 mm in diameter.
2.3. Differential Scanning Calorimetry (DSC) Measurements
The softening temperature and the melting point of the formulations were determined by
differential scanning calorimetry measurements with a Mettler-Toledo DSC 821e instrument in an
argon atmosphere (100 mL/min). The temperature was raised from +5 ◦C to +100 ◦C by 5 ◦C per
minute. Ten milligrams of the samples were put in 40 µL aluminum pans. The tops were holed,
then the pans were sealed.
2.4. X-ray Powder Diffraction (XRD) Analysis
Diffractograms of the raw materials (SBP, CA, KP, MZ, AMX, HPMC, ZnHA, ZnGlu) and the
formulations were obtained with a Bruker D8 Advance diffractometer (Bruker AXS GmbH, Billerica,
MA, USA) system with Cu K λI radiation (λ =1.5406 Å). Each sample was scanned at 40 kV and 40 mA
in the interval of 3◦–40◦ 2θ, at a scanning speed of 0.1/s and a step size of 0.010◦.
2.5. Mucoadhesion Measurements
Adhesion tests were performed with a TA-XT Plus (Texture analyzer, ENCO, Spinea, Italy)
instrument equipped with a 1 kg load cell and a cylinder probe with a diameter of 1.0 cm. Twenty
milligrams of the sample attached to the cylinder probe was placed in contact with a filter paper disc
impregnated with 50 µL mucin dispersion (8 w/w%, prepared in PBS (pH = 7.4)). A 2500 mN preload
was applied for 3 min (the compression speed was 2.5 mm min–1). The cylinder probe was then moved
upwards to separate the sample from the substrate at a prefixed speed of 2.5 mm min–1. Polymer
solutions, prepared by dissolving the solid polymers in PBS, were analyzed during the mucoadhesion
measurements where ZnHA and HPMC concentrations were 0.5, 1, 2, 5, and 10 w/w%. Ten parallel
measurements were performed.
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2.6. Investigation of the Swelling and Erosion of Formulations
A gravimetrical analysis was carried out in order to investigate the water absorption capacity of
the different formulations, and to examine the effects of the mucoadhesive polymers on the erosion
profile of the delivery systems. Prior to the measurements, the formulations were weighed with an
analytical scale and put in 10 mL of PBS solution thermostated at 37 ◦C for various time periods (0.5, 1,
2, 4, 6, 8, 24, 36, 48, 72, 96, and 168 h). Subsequent to the designated time period, the formulations were
weighed again, which was followed by drying at room temperature. After the formulations had totally
dried out, a third weight measurement was carried out. Evaluation of the changes in the mass of the
formulations could help the determination of the absorption capacity and the swelling related erosion
profiles. For each sampling time three parallels were applied.
2.7. Drug Dissolution Tests
The in vitro drug release profiles of formulation nos. 1, 2, 3, and 6 were determined.
The compositions were weighed with an analytical scale, put in 50-mm-long dialysis tubes
(Spectra/Por® Standard RC tubing, MWCO: 12-14 kD) and sealed with closures. The tubes containing
the formulations were placed in 7.5 mL of PBS solution thermostated at 37 ◦C. Drug release was
investigated for seven days and three parallel measurements were carried out. One milliliter of
samples was taken (at 0.5, 1, 2, 4, 6, 10, 24, 30, 48, 72, 96 and 168 h) and were replaced with 1 mL of PBS
solution. The active agents AMX and MZ were separated with an HPLC system (where necessary) and
quantified by a UV spectrophotometer attached to the HPLC at 230 nm.
The solution obtained was filtered through a 0.20 µm polyethersulfone syringe membrane filter
and injected directly into the HPLC system. The AMX and/or MZ content was quantified with a
Merck-Hitachi LaChrome Elite HPLC (Hitachi High Technologies America, Inc., Schaumburg, IL,
USA). AMX and MZ were measured on a Kinetex 250 mm × 4.6 mm column packed with 5 µm
EVO C18, 100 Å (Phenomenex Inc., Torrance, CA, USA). Elution was performed with 20:80 (v/v)
Methanol-NaH2PO4 (0.05 M) at a flow rate of 1 mL/min. Prior to the elution, the eluent was degassed
and filtered through a 0.45 µm pore-sized glass filter funnel. The run time was seven minutes. Detection
was performed via absorption at 230 ± 4 nm. 3 µL of sample were injected, and the elution was carried
out at a sample temperature of 25 ◦C and at a column temperature of 25 ◦C.
Quantitative determination was achieved by comparison with the spectra of standards. The stock
solutions of AMX and MZ (2 mg/mL) were prepared in PBS and stored at 4 ◦C. The stock solutions
were used within 24 h. Working standards (0.5, 1, 1.5, and 2 mg/mL) were prepared freshly by diluting
the stock solution with the mobile phase prior to the HPLC analysis. Calibration plots were freshly
prepared and were highly linear (R2 (AMX) = 0.9990 and R2 (MZ) = 0.9998). Limit of detection (LOD)
and limit of quantification (LOQ) of the quantitative determination was 3.308 and 10.020 µg/mL,
respectively, while in the case of amoxicillin and metronidazol, the resolution (RS) was 3.10.
Drug recovery tests were also performed, where the incorporated metronidazole was extracted
with water at the melting point of the lipid formulations. The results of the extracted drug amounts
corresponded to the incorporated drug amounts (99.50 ± 0.30%).
2.8. Microbiological Investigation
Microbiological study was conducted in order to measure the antibacterial effectiveness of the
developed formulations. Typical periodontopathogenic bacteria: Fusobacterium nucleatum (ATCC®
25586™), Parvimonas micra (ATCC® 33270™), Eikenella corrodens (ATCC® 23834™), Porphyromonas
gingivalis (ATCC® 33277™), Aggregatibacter actinomycetemcomitans (ATCC® 29524™), and Prevotella
intermedia (118710) control strains were used. A 1 McFarland standard concentration bacterial
suspension of each bacterial strain was made separately with 0.9% NaCl solution (in suspension
it is equivalent to approximately 3 × 108 colony forming units/mL). The suspension was spread
onto a horse blood agar plate, where then formulations were placed on. The concentration of the
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active agent(s) was 15 w/w%: 15 w/w% of AMX or MZ alone (formulations 1 and 2), or 7.5 w/w%
of both AMX and MZ (formulation 3). The delivery systems made with ZnHA contained 3 w/w%
ZnHA (formulation 4) or 3 w/w% ZnHA and 0.2 w/w% ZnGlu (formulation 5) or 3 w/w% ZnHA
and 15 w/w% MZ (formulation 6). After 24 h of incubation in anaerobic conditions, the diameter of
the inhibition zones was measured. The formulations were then put on a new horse blood agar plate,
also inoculated with 1 McFarland standard concentration freshly made bacterial suspension of each
of the above-mentioned bacterial strains. The plates were then put in an anaerobic chamber for 24 h.
This was repeated until no inhibition zone could be detected.
3. Results and Discussion
3.1. Differential Scanning Calorimetry (DSC) Measurements
DSC was used to determine the softening temperature and the melting point of the formulations.
The lipid base of the compositions was SBP, which is often used as a base for suppositories [29].
In our measurements, it has a melting point at 39.08 ◦C (Figure 1).
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Figure 1. DSC curves of pure components (Kolliphor RH40, Suppocire BP and Cetostearyl alcohol) and
formulations containing 15 w/w% of amoxicillin, 15 w/w% of metronidazole, 7.5 w/w% of amoxicillin
and metronidazole, 3 w/w% of zinc hyaluronate, 3 w/w% of zinc hyaluronate and 0.2 w/w% of zinc
gluconate, and 3 w/w% of zinc hyaluronate and 15 w/w% of metronidazole.
Cetostearyl alcohol is mostly used as a surfactant, a co-surfactant or as a viscosity increasing
agent in semisolid formulations. According to our DSC measurements, the melting point of the pure
component is at 61 ◦C (Figure 1.). In our earlier study [30], we presented that where CA remains
partially in a crystalline state; thus, sustained drug release could be achieved.
The esults of DSC measurements show that K lliph r RH40 has a congealing temperature
approximately betw en 20—30 ◦C (Figure 1), which corr sponds with the lit rature data [29].
No sharp peaks could be perceived on the curves belonging to the polymers (zinc hyaluronate
and Methocel E4M), and zinc gluconate in this temperature range (10—100 ◦C). Glass transition of
these components starts over 50 ◦C (Figure 1.)
Formulation nos. 1–6 were examined to investigate the possible modifying effect of the
incorporated drugs and excipients on melting point. Antibiotics or other suspended materials may
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partially dissolve in the lipid base, therefore, the effect of various incorporated components of different
amounts on the melting point was also investigated.
In all formulations, the sharp peaks of SBP and CA disappeared, even the two peaks of CA
morphed into one, and shifted to temperatures between the melting points of the two pure components.
At approximately 30 ◦C, a moderate melting can be observed, but total melting only occurs between
40 and 50 ◦C. A moderate melting starts at 30 ◦C, which supports the softening of the systems, but,
as there are components with melting points at about 50 ◦C, which suggests the presence of a coherent
structure at body temperature; thus, total melting of the formulations will not occur, and sustained
drug release may be possible.
The type of the drug did not influence the melting point greatly, but differences in the shape of
the curves are noteworthy. In the case of formulations containing zinc salts or amoxicillin, peaks at
approximately 50 ◦C (probably the two fused peaks of CA) broadened, meaning an earlier onset of
melting, while metronidazole containing ones show sharper peaks.
By the thorough analysis of the DSC results, we could conclude that no peaks of any curve
belonging to different formulations could be associated with the decomposition of any component,
thus, the constituents are expected to be stable in this temperature range.
3.2. XRD Analysis
Active ingredients were suspended in the melted lipids. XRD analyses were carried out to
investigate their final state (suspended or dissolved). The presence of solid crystals is indicated by
sharp peaks in the diffractograms, while dissolved components, as they do not possess a crystalline
structure, are not detectable. The amorphous structure is often a substantial feature of polymers; thus,
the crystalline structure and its characteristic peaks are absent from the diffractograms.
All of the components, except for HPMC, Kolliphor RH40, zinc hyaluronate, and zinc gluconate,
have a crystalline structure according to the XRD diffractograms presented in Figure 2.
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amoxicillin, metronidazole, zinc hyaluronate, zinc gluconate, Methocel E4M) and formulations
containing 15 w/w% of amoxicillin, 15 w/w% of metronidazole, 7.5 w/w% of both of amoxicillin
and metronidazole, 3 w/w% of zinc hyaluronate, 3 w/w% of zinc hyaluronate and 0.2 w/w% of zinc
gluconate, and 3 w/w% of zinc hyaluronate and 15 w/w% of metronidazole.
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SBP and CA have similar molecular structures, which will result in analogous diffractograms.
This means that in the diffractograms of the formulations containing all of the components, it is hard
to differentiate between the two lipid components. The more intensive peak of CA could overlap with
and cover the peak of SBP at the same 2θ value in the preparations. This peak, which belongs to CA,
has decreased in intensity in the diffractograms of the formulations, which implies that the crystallinity
of CA has decreased, which is in accordance with the DSC results, where the two peaks of pure CA
have fused together and shifted to a lower temperature range.
A characteristic peak linked to SBP at the 2θ value of approximately 5◦ is present in all
formulations with varied intensity, also indicating the crystalline structure of the lipid base.
The characteristic peaks of AMX and MZ could be separated from those of the lipid components.
The presence of characteristic peaks in the diffractograms is the sign of solid particles in the
formulations. AMX and MZ have a characteristic peak at the 2θ value of 18.1◦ and 12.3◦, respectively.
Peaks at the mentioned 2θ values could be observed in the diffractograms of formulations containing
AMX or MZ.
The presence of ZnHA or ZnGlu in the preparations could not be demonstrated by this experiment
because of their amorphous structure to which no characteristic peak belongs in an XRD diffractogram.
The partially crystalline form of the lipid matrix (CA and SBP) could contribute to the coherent
structure of the system, which does not melt at body temperature, thus providing sustained release of
antibiotic compounds, while the suspended form of the drugs and antimicrobial agents may provide
a more stable form, therefore protecting the drugs from the negative effects of the environment and
decomposition as well.
3.3. Investigation of the Mucoadhesive Properties of the Applied Polymers
Subsequent to insertion into the periodontal pocket and wetting of the lipid system,
the mucoadhesive polymers at the interface of the lipid and the periodontal fluid get hydrated,
swell, and form a gel layer, providing adhesion to the application site.
The mucoadhesive properties of the polymers were investigated by means of a tensile test,
which is an in vivo-like mucoadhesion method because it mimics the adhesion to a biological surface.
Adhesive force and work were determined on the basis of the force-distance curve obtained during the
tensile test (Table 2). In this measurement, a larger concentration range of polymers was investigated.
The larger concentration range of polymer solutions could mimic the gel layer formed at the surface of
the lipid formulation; therefore, the mucoadhesion properties of the delivery system.
Table 2. Adhesive force and work of the gels at different polymer concentrations. Mean values and SD,
n = 10. (ZnHA = Zinc hyaluronate; HPMC = Methocel E4M, hydroxypropyl methylcellulose).
Polymer Polymer Conc. (%)
Adhesive Force (mN) Adhesive Work (mN.mm)
Mean± SD Mean± SD
ZnHA
0.5 1579.0 71.1 167.3 9.9
1 1786.8 230.9 202.9 37.6
2 1789.6 98.9 207.1 19.6
5 2299.5 111.2 397.9 30.8
10 2514.4 69.6 1166.6 163.9
HPMC
0.5 73.5 28.3 16.2 6.3
1 145.6 62.3 28.7 17.8
2 325.7 137.1 60.7 16.1
5 607.8 358.7 180.7 64.5
10 779.4 265.5 527.1 170.0
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In our measurements, in both cases, the adhesive force and work continuously increased
with increasing polymer concentrations; ZnHA showed remarkable adhesion over the whole
investigated polymer concentration range, indicating better mucoadhesion to the model surface;
thus, ZnHA may provide a better mucoadhesive feature for the lipid formulations than HPMC, and the
multipotent (adhesive and antimicrobial) characteristics of the former excipient can be beneficial in
periodontal therapy.
3.4. Swelling and Erosion Profiles of Delivery Systems
In addition to melting and softening, swelling and erosion of the lipid formulation can also affect
drug release. In this case, the swelling of the polymer can result in a gel layer on the surface of the
delivery system, and then this layer can be slowly removed thanks to the elimination mechanisms
in the oral cavity and periodontal pocket. In addition to this mechanism, the melted lipid and the
surfactant can also be eliminated from the formulation by emulsification with the produced oral
biological medium, the gingival crevicular fluid.
In our experiments the swelling ratio (%) was calculated as follows [31]:
Swelling ratio (%) = ms / mo × 100% (1)
where ms is the mass of the formulations after immersed in water for the specified time and mo is the
mass of the original formulations (prior to the immersion into water).
During the measurements, delivery systems were immersed into purified water to investigate the
swelling and erosion properties of the different preparations, because different antimicrobial agents
and mucoadhesive polymers are incorporated into the systems. The swelling ratio of the different
compositions can be observed in Figure 3a,b, while the erosion profiles are shown in Figure 4a,b.
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Based on the swelling profile, two groups can be distinguished. Swelling ratio of formulations
containing ZnHA and/or a higher amount of MZ shows a higher water absorption capacity than
formulations with AMX or lower concentrations of MZ and HPMC as polymer; the former group had a
maximum swelling ratio of approximately 560%, while the latter group was only approximately 300%.
This phenomenon may be driven by the different swelling and solubility of components: i) ZnHA
is a material possessing a strong water absorption capacity, and ii) MZ owns a sparingly water-soluble
feature but better than amoxicillin. Because of the higher water absorption-capacity of ZnHA and
better solubility of MZ, water could access the lipid structure with ease resulting in higher swelling of
formulations; ZnHA may bind a very large amount of water and break the coherent lipid structure,
and through the generated superficial microgaps more ZnHA particles become accessible to water,
thus binding more medium. MZ may work in a highly similar way, but in this case the applied
polymer (HPMC) binds the water. The better solubility of MZ compared to AMX, also contributes to
quicker dissolution from the systems, and the dissolved MZ (leaving capillaries in the structure) may
provide water with a trouble-free entry accessing polymer particles incorporated into the delivery
systems. The more drug is dissolved from the preparations, the more capillaries are made, and through
more capillaries, more polymer particles may be accessed, which results in a higher water binding.
When ZnHA and a high concentration of MZ (15 w/w%) are applied together, no extra swelling can be
observed. This phenomenon can be explained by the structure of the formulations, the swelling power
of the polymers may not be vigorous enough to destroy the coherent solid structure of the delivery
system; thus, combining the two components (MZ and ZnHA) did not result in over-swelling.
AMX and lower concentrations of MZ are not capable of generating the same effect due to the
creation of fewer capillaries because of the poorer solubility of amoxicillin compared to MZ and the
lower concentration of MZ; therefore, the swelling of those systems remains below the level provided
by the formulations having ZnHA or more MZ incorporated into them.
Accordingly, the swelling profiles of the different formulations may be dependent on the
incorporated materials, their attributes and the strength of the coherent lipid structure.
Erosion ratio (%) was calculated from the following equation [30]:
Erosion ratio (%) = mo−md/mo × 100% (2)
where mo is the mass of the original formulations and md is the mass of the dried formulation after the
swelling and erosion measurements.
In contrast with the results of the swelling measurements, the erosion of different compositions
are not highly different from each other (Figure 4a,b). The weight of all formulations has decreased
to approximately 60% of that of the original ones. Two main mechanisms may control the erosion
of the drug delivery systems. One is the emulsification of components melted at body temperature
(37 ◦C) with water. The other is the swelling power of incorporated polymers, destroying the coherent
structure, and the erosion of the gel layer formed at the surface. The similarities in the erosion
profiles can highlight that the destruction of delivery systems may be more likely to be defined by
the emulsification of the melted lipid components, as the lipid composition and ratio and, therefore,
the basic structure of the different compositions, are almost the same. The swelling experiments also
suggest the same findings, because the strength of the coherent structure could limit the swelling
of polymers.
3.5. Investigation of Drug Release from Formulations
Drug dissolution measurements were carried out in order to evaluate the drug release profiles of
the prepared formulations which contain MZ. An HPLC method was used to quantify the dissolved
drug from the preparations.
The amount of released MZ from formulations containing the antibiotic drug is shown in Figure 5.
Preparations containing 15 w/w% MZ and HPMC or ZnHA have shown similar drug release profiles.
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A plateau phase commencing at approximately at the 100th hour is indicated in both cases, which is in
accordance with a total drug release.Pharmaceutics 2019, 11, x FOR PEER REVIEW 11 of 18 
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(15 w/w% metronidazole, 3 w/w% zinc hyaluronate and 15 w/w% metro idazole, and 7.5 w/w%
amoxicillin and 7.5 w/w% metronidazole).
However, the drug release curves of formulations containing 7.5 w/w% MZ indicates that only
one-third of the amount was liberated from the preparations despite the fact that half of the amount
had been incorporated into the compositions.
The drug release mechanism can be characterized with the following exponential equation:
Mt/ ∞ = k tn (3)
where Mt/M∞ is the fraction of drug released, k is the kinetic constant and n is the release exponent
describing the mechanism of the release.
On the basis of literature data, in case of swelling controlled cylindric drug delivery systems,
if the release exponent is 0.45, the dug release mechanism is a Fickian diffusion, while the release
exponent is between 0.45 and 0.89, the release corresponds to anomalous (non-Fickian) diffusion [32].
In our case, the highly swellable formulations (Formulations 2 and 6) showed non-Fickian diffusion,
which indicates that Fickian diffusion coupled with the swelling of the incorporated polymer. In the
formulation where swelling is moderated (Formulation 3) alone Fickian diffusion characterizes the
drug release (n = 0.4567) (Table 3).
Table 3. Release exponent (n), kinetic constant (k) and R2 values of curves fitted on the drug release
curves of formulations 2, 3, and 6.
Formulation No. n k R2
2 . 1555 0.9802
3 0.4567 995.6 0.9926
6 0.6671 1360.6 0.9880
The phenomenon detailed above in Section 3.4. may be in the backgroun of such results. MZ,
which is a more soluble material in water compared to AMX, could be liberated more quickly from
formulations cr ating capillaries, which contribute to a higher swelling and therefore allow water to
access all th suspende drug in the delivery systems. On the contrary, wh n smaller amounts of MZ
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are incorporated into the delivery systems with AMX—a substance with lower water solubility—fewer
capillaries may be formed during drug release, permitting less water to penetrate the systems and
resulting in non-complete drug dissolution.
The application of ZnHA did not change the release profile, which can be explained by the similar
swelling and erosion profiles of the formulation containing 15 w/w% MZ with and without ZnHA.
Summarizing the results of drug dissolution testing, a sustained release of drugs could be achieved
with these compositions, and the main factors affecting drug release are swelling (driven by the applied
hydrophilic components such as polymer, active ingredients and their concentration) and the strength
of the coherent lipid structure.
3.6. Microbiological Investigation
Numerous different species of microorganisms may be present in the oral cavity or on the dental
surfaces. The composition of the oral microbiota varies widely from person to person, from place to
place and naturally with dietary habits [33,34].
Many journal articles aim to define the species of bacteria which have a contribution to the
initiation and progression of periodontal disease [33–41], but the high number of different strains
and cultivation difficulties make it almost impossible. Moreover, only a small percentage of the
subgingival oral microbiota has a role in disease pathogenesis [42,43]. Pathogen organisms which
could be linked to and may have correspondence to the disease are the following: Porphyromonas
gingivalis, Prevotella intermedia, Bacteroides forsythus, Actinobacillus actinomycetemcomitans, Treponema
denticola, Tannerella forsythia, Fusobacterium nucleatum, Fusobacterium periodonticum, Prevotella intermedia,
Prevotella nigrescens, Parvimonas micra, Campylobacter gracilis, Campylobacter rectus, Campylobacter showae,
Eubacterium nodatum, Streptococcus constellatus, Eikenella corrodens, Streptococcus spp., etc. [33,42–45].
According to Kolenbrander et. al. [45], these species can be separated into two categories concerning
plaque formation. Species in the first category—initial colonizers—are thought to stick to the tooth
surface and proliferate. The second group—late colonizers—binds to the first group of bacteria via
different interactions.
In our formulations, AMX or MZ was incorporated in 15 w/w% concentration, and a system
containing 7.5/7.5 w/w% AMX and MZ was also compiled. In addition to these formulations, ZnHA,
ZnHA and ZnGlu, and ZnHA and MZ containing ones were also created and investigated.
AMX, which is a semi-synthetic penicillin derivative, is known to be effective against many
aerobic or anaerobic Gram-positive and Gram-negative bacteria [13,46].
MZ is an antibacterial agent, included in the nitroimidazole group. Numerous bacteria and
protozoa—even anaerobes—are known to be susceptible to MZ [7,47].
In periodontal disease therapy, MZ and AMX may be used as an adjunct to scaling and root
planning therapies locally or systematically [48–50].
Hyaluronic acid is a naturally occurring polysaccharide of the extracellular matrix of connective
tissue, synovial fluid, and soft periodontal tissues as well. Its application in the treatment of the
inflammatory process is established in different medical areas such as orthopedics, dermatology,
and ophthalmology. In the treatment of periodontal diseases, hyaluronic acid shows anti-inflammatory
and anti-bacterial effects [51].
Zinc salts may have a beneficial effect when used in mouth rinses, can possibly decrease plaque
formation by inhibiting glycolytic enzymes and may prevent the attachment of bacteria to the tooth
surface [52]. These salts administered in combination with other antimicrobial agents may show a
synergism by means of antibacterial effect [53].
In view of the beneficial properties of hyaluronates, zinc hyaluronan was chosen as a combined
mucoadhesive and antimicrobial agent for our other set of formulations.
The antibacterial effectiveness of samples with Zinc hyaluronate was also measured to determine
if the polymer has an antibiotic effect alone or in combination with other molecules like zinc gluconate
or metronidazole.
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In our microbiological investigation, where the antimicrobial activity of our formulations was
measured, we used six different strains of oral pathogen bacteria, which may contribute to the initiation
of periodontitis. These were the following: Eikenella corrodens, Prevotella intermedia, Parvimonas micra,
Fusobacterium nucleatum, Aggregatibacter actinomycetemcomitans, and Porphyromonas gingivalis.
Eikenella corrodens—a facultative anaerobic, Gram-negative bacterium—is a human (mostly
oral) pathogen. E. corrodens appears to be susceptible to beta-lactam antibiotics, but resistant to
metronidazole [54].
Parvimonas micra (also known as Peptostreptococcus micros or Micromonas micros)—an anaerobic,
Gram-positive coccus—is the member of the normal human gastrointestinal flora [55]. According
to Rams et al., it shows high susceptibility to penicillin but metronidazole seems to be less effective
against the bacterium [56].
Prevotella intermedia—a Gram-negative anaerobic bacterium with black pigments—is often
connected with oral and subgingival diseases. P. intermedia shows susceptibility to penicillin and
metronidazole [57].
Fusobacterium nucleatum—a mostly oral and periodontal anaerobic pathogen—can be linked to a
variety of human diseases. Strains isolated from endodontic infections seem to be highly sensitive to
amoxicillin and a little less susceptible to metronidazole [58,59].
Aggregatibacter actinomycetemcomitans—a Gram-negative, facultatively anaerobic rod—is
frequently associated with most forms of periodontitis and numerous oral infections. Amoxicillin is
effective against the bacterium, while it shows much less susceptibility to metronidazole [60,61].
Porphyromonas gingivalis—an obligately anaerobic, Gram-negative black-pigmented rod—is the
most commonly linked microorganism to periodontal disease. According to susceptibility tests,
P. gingivalis is sensitive to amoxicillin and metronidazole [62,63].
Agar plates were 90.0 mm in diameter, thus, the largest possibly detectable inhibition zone could
be around 90.0 mm.
The results of the microbiological investigations can be found in Figure 6.
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intermedia.
The largest measurable inhibition zone wa 74.0 mm in diameter and was because of an amoxicillin
containing formulation an agar plate i oculated with Eikenella corrodens after the first 24 h.
According to our measurements, Parvimonas micra was the most sensitive microorganism to AMX
containing formulations as the compositions could provide 17 days of effective drug release, while the
least susceptible pathogen was Eik n lla corrodens with only eight days of growth inhibition.
MZ susceptibility was slightly lower, as the effect against the m st sensitive bacterium
(Porphyromonas gingivalis) was only nine days. Eikenella corrodens was the least susceptible to MZ
as on the first 2 days no growth could be detected, but after two days bacteria were growing all over
the agar plate, and there was no inhibition zone arou d the formulation. This result is in accordance
with the literature data, where it was established that Eikenella corrodens is resistant to MZ [46].
Compositions containing 7.5 w/w% of AMX and MZ did not provide larger inhibition zones than
formulations containing only one antimicrobial agent as the antimicrobial effect lasted for shorter time
periods. P. gingivalis was an excep : this bacterial stra n was the only one with higher susceptibility
to the combination of the two antimicrobial drugs. In most cases, the growth inhibition effect of
combinations lasted longer than that of metronidazole. This could have been possible due to the
more potent antimicrobial effect of AMX. Lower susceptibility to the combination of AMX and MZ
compared t only AMX containing formulations may be due to the decreased concentration of AMX in
the combination containing compositions and the lower susceptibility of bacteria to MZ.
Whereas MZ is less potent against Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum,
and Parvimonas micra [56,58–61], with our formulations the growth inhibition effect can be provided
for up to 3 day .
Susceptibility to ZnHA is different among various bacterial strains. Aggregatibacter
actinomycetemcomitans and Eikenella corrodens show resistance to ZnHA, but combined with ZnGlu,
a longer effect can be observed in case of Aggregatibacter actinomycetemcomitans. Eikenella corrodens remains
unsusceptible to the combination of ZnHA and ZnGlu.
According to the results, the same susceptibility characterizes Porphyromonas gingivalis and
Prevotella intermedia when using ZnHA alone or in combination with ZnGlu.
In case of Parvimonas micra and Fusobacterium nucleatum, the results show that higher efficiency
may be achieved by administering a combination of ZnHA and ZnGlu instead of using only ZnHA.
The results imply that the combination of MZ and ZnHA provides a synergistic effect:
formulations containing both ZnHA and MZ provided longer growth inhibition against the
microorganisms than the active agents alone. The synergistic effect is most conspicuous against Eikenella
corrodens where formulations with MZ only lasted for two days, and ZnHA had no antibacterial effect
against the bacteria, while the combination showed a nine-day effect.
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All in all, the outcome of the antimicrobial investigation of ZnHA supports that alone it may not
be effective enough, but a combination with an antimicrobial drug (e.g., MZ) may provide a synergistic
and—in this case—a longer positive effect.
While the in vitro dissolution of AMX could not be detected, because the antibiotic had
decomposed thanks to the test environment (aqueous medium at 37 ◦C), the results of the
microbiological investigation imply that AMX stays stable when incorporated into the lipid
preparations, as it may provide 18 days of growth inhibition. (In this experiment, anaerobic
environment was provided, and the agar plates were changed day-by-day, which enabled amoxicillin
to remain stable in the aqueous agar medium.) This finding and the swelling experiments suggest that
the combination of AMX and a highly hydrophilic polymer with strong water binding capacity may
not be beneficial, because the sustained release of AMX could easily result in the decomposition of the
drug, even in the formulation prior to its dissolution.
4. Conclusions
An anhydrous lipid-based drug delivery system for the treatment of periodontitis was successfully
prepared and investigated. Possible administration and positive effect during disease treatment were
confirmed by the results of different measurements.
According to the DSC measurements, the melting of formulations starts at body temperature,
but total melting only occurs over 40 ◦C, which allows the presence of a coherent structure and
provides sustained drug release.
X-ray diffraction analysis indicates that the antibiotics are in a suspended form in the compositions,
and lipid components have a crystalline structure, which may also contribute to a prolonged drug
release and antimicrobial effect.
Thanks to the complex composition, our lipid formulations are swellable and degradable systems.
On the basis of our results, their swelling can be driven by the applied hydrophilic components
(polymer, active ingredients), their concentration and the strength of the coherent lipid structure,
while their erosion may be controlled mainly by the emulsification of the melted lipid components.
In formulations, where swelling is remarkable, Fickian diffusion is coupled with the swelling
of the incorporated polymer. Because of this phenomenon, which is indicated in the shape of the
diffusion curves, an anomalous (non-Fickian) diffusion model could be fitted to the diffusion curves.
The results of drug release and antimicrobial investigations show that with AMX incorporated into the
delivery systems, long drug diffusion can be obtained with a high antimicrobial effect. AMX can be
protected against degradation in hydrophilic circumstances at the periodontal pocket by using these
lipid formulations, which is suggested by our antimicrobial investigations. The sustained drug release
of MZ can also be provided, which may enable taste-masking and direct application of MZ in the
oral cavity without decreasing patient compliance. The combination of ZnHA and MZ improved the
antimicrobial characteristics of formulations compared to formulations containing only ZnHA or MZ.
These findings suggest that—when administered together—the two compounds have a synergistic
effect and might be a good alternative for patients allergic to penicillin and their derivatives.
In order to improve the residence time of melted lipid formulations in the periodontal pocket,
mucoadhesive polymers were applied. In our experiments, ZnHA had better adhesivity compared
to HPMC, and, additionally, it has a potential antibiotic feature. Nevertheless, the application of a
highly hydrophilic polymer with a strong water absorption capacity is questionable when the drug,
e.g., AMX, is not stable in aqueous circumstances.
The developed and evaluated lipid formulations containing antimicrobials may offer a solution to
such problems of local periodontal therapy as long-lasting effect. Moreover, the combination of MZ
and ZnHA can provide an effective antimicrobial therapy for penicillin-allergic patients.
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Purpose: Electrospun PLA ﬁber devices were investigated in the form of ﬁber mats and disks.
Metronidazole was used as an active agent; its concentration was 12.2 and 25.7 wt% in the devices.
Methods: The structure was studied by X-ray diffraction and scanning electron microscopy,
drug release by dissolution measurements, while the antimicrobial efﬁciency was tested on ﬁve
bacterial strains.
Results: The XRD study showed that the polymer was partially crystalline in both devices,
but a part of metronidazole precipitated and was in the form of crystals among and within the
ﬁbers. Liquid penetration and dissolution were different in the two devices, they were faster
in disks and slower in ﬁber mats, due to the morphology of the device and the action of
capillary forces. Disks released the drug much faster than ﬁber mats. Although the release
study indicated fast drug dissolution, the concentration achieved a plateau value in 24 hrs for
the disks; the inhibition effect lasted much longer, 13 days for bacteria sensitive to metro-
nidazole. The longer inhibition period could be explained by the slower diffusion of
metronidazole located inside the ﬁbers of the device.
Conclusion: The results suggest that the devices may be effective in the treatment of
periodontitis.
Keywords: drug release devices, ﬁber mats, disks, morphology, dissolution, capillary forces,
diffusion, antimicrobial, inhibition
Introduction
Periodontitis is an inﬂammatory disease resulting from the overgrowth of subgin-
gival polymicrobial community in susceptible hosts affecting the tissues surround-
ing the teeth. The inﬂammation of periodontal tissue causes bone destruction by
osteoclastic resorption together with tissue destruction, and the detachment of
junctional epithelium result in periodontal pocket formation. Conditions in the
periodontal pocket are suitable for bacterial proliferation and result in dysbiosis
owing to a breakdown in host-microbe homeostasis.1,2 This disease is the most
prevalent reason for tooth loss among adults.3
The elimination of bioﬁlm and/or hard deposits (mineralized bioﬁlm) is the
cornerstone of periodontal treatment. The management of periodontal disease
includes the mechanical removal of bioﬁlm with or without the adjunctive use of
systemic antibiotics.4 Systemically administered antibiotics may not be present in
sufﬁcient concentration in the periodontal pocket; therefore, they are often ineffec-
tive, while the common side effects of antimicrobial therapy could occur.5
Numerous publications published in the open literature report investigations on
local delivery systems containing antimicrobial drugs, which – alone or in combination
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with other dental procedures – may result in a more efﬁcient
treatment.5–10 The local administration of delivery systems
with incorporated antibiotics is a promising approach to
treating periodontitis. The introduction of devices containing
antibiotics into the periodontal pockets could result in efﬁ-
cient therapy with limited side effects and reduced risk of
developing drug-resistant microbes. The comparison of local
to systemic drug delivery shows that 100-fold larger concen-
trations of the antimicrobial agents can be achieved at sub-
gingival sites, which can lead to a more efﬁcient therapy.11
Numerous local drug delivery systems such as ﬁbers, strips,
ﬁlms, injectable gels, micro- and nanoparticulate systems,
vesicular systems, and in-situ forming implants were devel-
oped for this purpose during the last decades.5–10
The electrospinning technique has received considerable
attention lately because it is an affordable, cost-effective
and easy-to-use technology for creating nanoﬁbrous scaf-
folds for tissue engineering purposes, as well as drug deliv-
ery systems and wound dressings.12–15 The advantages of
electrospun drug delivery systems are numerous: i) large
drug loading capacity (up to 60%),16 ii) different polymers
may be applied depending on the compatibility of the active
pharmaceutical ingredients, iii) the process is simple and
cost-effective,17 and iv) the modulation of drug release can
be achieved as well.18,19
Sustained drug release can be achieved by both non-
biodegradable and biodegradable polymers. Biodegradable
polyesters such as PLA, polyglycolic acid (PGA), poly
(lactic-co-glycolic) acid (PLGA), and polycaprolactone
(PCL) have already been applied18 for this purpose.
Information about research describing polymer or biopo-
lymer-based electrospun delivery systems containing dif-
ferent antimicrobial agents, which may be applied with
success for the treatment of periodontitis, is available in
the literature.20–25 Fiber mats fabricated using the electro-
spinning method may be suitable for the treatment of
periodontal disease and they could provide prolonged
drug release.20
The goal of the current work was to develop and inves-
tigate locally administrable, PLA-based, metronidazole-
containing devices for the treatment of periodontal disease.
The devices were composed of electrospun ﬁber mats as
received from the spinning process and compressed disks
prepared from the mats. The drug used was metronidazole,
which is known to be an active pharmaceutical ingredient
(API) with an undesirable bitter taste, hindering its local
application as a drug for periodontal treatment. It is
expected that the encapsulation of metronidazole into
a hydrophobic polymer matrix, sustained release, and prob-
ably a lower effective concentration in the oral cavity might
eliminate this problem. We assumed that mats enable the
free ﬂow of the exudate in the periodontal pocket. On the
other hand, disks provide drug delivery devices with
a standardized geometry (surface, width) and equal drug
content and facilitate the treatment of tight pockets.
Accordingly, we analyzed the effect of drug concentration
and the form of the delivery device on the kinetics of drug
release in detail. Practical consequences are brieﬂy men-
tioned in the ﬁnal section of the paper.
Materials and Methods
Materials
Spinning solution was made by dissolving polylactic acid
(PLA) (Ingeo 4032D type, NatureWorks LLC., Minnetonka,
MN, USA) in a mixture of dichloromethane and dimethyl
sulfoxide (Molar Chemicals Ltd., Halásztelek, Hungary). For
the spinning of ﬁbers containing an active agent, metronida-
zole (Ph. Eur. 8., Hungaropharma Plc., Budapest, Hungary)
was also dissolved in the same solvent mixture in different
concentrations.
For in vitro drug diffusion measurements, a pH=7.4
phosphate-buffered saline (PBS) solution was used. The
buffer solution was prepared by dissolving 8 g/dm3 NaCl,
0.2 g/dm3 KCl, 1.44 g/dm3 Na2HPO4 · 2 H2O, and 0.12 g/
dm3 KH2PO4 (Ph. Eur. 8., Hungaropharma Plc., Budapest,
Hungary) in distilled water. The pH was adjusted to 7.4 by
adding an adequate amount of 0.1 M HCl to the solution.
Methods
Fiber Spinning
PLA ﬁbers containing various amounts of metronidazole
were prepared by coelectrospinning, which is a widely
used and cost-effective method to produce nanoﬁbers espe-
cially for tissue engineering and regenerative medicine.26
The ﬁbers were spun at ambient temperature at 15-kV
voltage, 10-cm collector distance, and a feeding rate of
3 cm3/hr. The solvent used was the 80/20 vol% mixture of
dichloromethane and dimethyl sulfoxide. The solution con-
tained the polymer in 10 wt%, while the amount of the
active component was changed from 0 to 3 wt% of the
solution. The random array of ﬁbers was compressed to
disks of 13-mm diameter for further testing.
Sample Preparation
The metronidazole concentration of the ﬁbers was 12.2 and
25.7 wt%, the latter corresponding to the metronidazole
Budai-Szűcs et al Dovepress
submit your manuscript | www.dovepress.com
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concentration of the saturated spinning solution. Neat elec-
trospun ﬁbermats taken directly from the aluminum collector
ﬁlm and round-shaped, compressed disks were used for the
analysis of release kinetics and microbial activity. The disks
were obtained by compressing approximately 10–15 mg of
the neat ﬁber under 1 kN pressure for 30 s in a pellet die of
13-mm diameter (Specac Atlas Manual Hydraulic Press 15T
and Specac 13 mm Pellet Press Die, Specac Ltd., Orpington,
Kent, UK).
Scanning Electron Microscopy
The appearance of the disks and ﬁbers and the diameter of the
latter were investigated by scanning electron microscopy
using a Jeol JSM 6380 LA apparatus. The micrographs
were recorded at different magniﬁcations using 15-kVaccel-
eration voltage. Before viewing, the ﬁbers were sputtered
with gold. The determination of ﬁber thickness was done
with the Image Pro Plus 6 software.
X-Ray Diffraction Analysis
A Bruker D8 Advance diffractometer (Bruker AXS GmbH,
Karlsruhe, Germany) with CuKα radiation (λ = 1.5406 Å)
was used for the XRD analysis. The samples were scanned
at 40 kV and 20 mA from 3° to 40° 2θ angle at a scanning
rate of 0.1 °/s and a step size of 0.01°.
Penetration of the Aqueous Medium, Wetting
The behavior of the devices in contact with water was
studied with an OCA Contact Angle System (Dataphysics
OCA 20, Dataphysics Inc., GmbH, Germany). The contact
angle of water droplets was determined on the neat electro-
spun ﬁbers, the disks prepared from them as described
above, and on a metronidazole pastille of the same size.
The measurement was done with a water droplet of 10 μL
volume, which was dropped from a calibrated syringe onto
the surface of the various devices. Contact angle was mea-
sured instantly after the placement of the droplet, as well as
10 and 20 mins afterward. Five parallel measurements were
done on each sample.
In vitro Drug Release Study
The in vitro drug release proﬁles of the nanoﬁbers were
determined by the measurement of dissolution followed
by UV-Vis spectroscopy. Disks (0.014–0.017 g) and neat
ﬁber mats (0.012–0.016 g) were weighed and put into
7.5 mL of pH=7.4 PBS solution thermostated at 37°C.
Samples of 1.0 mL volume were taken at 0.5, 1, 4, 6, 10,
24, 30, 48, 72, 96, and 196 hrs and replaced with 1.0 mL
of fresh PBS solution. Drug release was followed for 7
days. The concentration of the released metronidazole
was determined by UV-Vis spectrophotometry (Helios α
Thermospectronic UV-spectrophotometer v4.55, Unicam:
Thermo Fisher Scientiﬁc, Waltham, MA) at 318 nm.
Blank samples (PLA ﬁber mats and disks) were also
treated in the same way as reference, but in their case
no absorbance was detected in the wavelength range of
200–900 nm with spectrophotometric analysis.
Antimicrobial Test
The antibacterial efﬁciency of the disks containing 12.2 or
25.7 wt% metronidazole was determined as well. The
control strains of ﬁve bacteria were used in the study:
Fusobacterium nucleatum (ATCC® 25586™), Parvimonas
micra (ATCC 33270™), Eikenella corrodens (ATCC
23834™), Aggregatibacter actinomycetemcomitans (ATCC
29524™), and Prevotella intermedia (118710). All measure-
ments were carried out according to the same protocol.
A bacterial suspension of one McFarland standard concentra-
tion, which is equivalent to approximately 3×108 colony-
forming units/mL in the suspension, was freshly prepared
with normal saline solution. Equivalent portions of the suspen-
sions were then spread onto a horse blood agar plate and disks
of equal weight were placed on it. The diameter of the inhibi-
tion zone was measured after 24 hrs of incubation in an
anaerobic chamber. The disks were then put again on a new
horse blood agar plate, also inoculated with a bacterial suspen-
sion of one McFarland standard concentration freshly made
from the bacterial strains mentioned above. The plates were
then put into an anaerobic chamber for 24 hrs. The procedure
was repeated until no inhibition zone could be detected, or for
a maximum of 14 days. Three parallel measurements were
carried out for every formulation and bacterial strain.
Statistical Analysis
The results of the in vitro drug release study were analyzed
statistically with GraphPad Prism version 5 software. Two-
way ANOVA analysis was used with Bonferroni post-tests.
A level of p ≤ 0.05 was considered as signiﬁcant, p ≤ 0.01 as
very signiﬁcant, and p ≤ 0.001 as highly signiﬁcant.
Results and Discussion
The results are discussed in several sections. First, results
related to the structure of the devices are presented and
then the penetration of the dissolution medium into them is
analyzed. Drug release and the results of the microbiolo-
gical testing are discussed in the last two sections together
with a few remarks on practical relevance.
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Structure
PLA has a regular molecular structure and can crystallize
under appropriate conditions, and metronidazole is also
a crystalline material. The solubility of the drug in the poly-
mer and its diffusion into the surrounding medium depend
on the structure of the components and on their distribution.
Metronidazole is a water-soluble, polar substance, the solu-
bility of which is small in the polymer. Accordingly, some of
the drugs can be dissolved, but another part precipitates and
is located among or inside the ﬁbers as crystals. Structure
determines drug release and its control allows the regulation
of efﬁciency through modiﬁed drug release.
The structure was studied by XRD analysis and SEM
microscopy. The crystallization of PLA is slow; thus,
products prepared from this polymer are usually amor-
phous. On the other hand, the evaporation rate and the
possible presence of residual solvent might result in the
crystallization of the polymer. The XRD study showed that
the ﬁbers were partially crystalline at the time of the
measurements and the release, as well as during the micro-
biological measurements. As expected, the compression of
the mat into disc did not change the structure.
The incorporation of metronidazole may change the
structure of the polymer. The drug may act as a nucleating
agent, but it can change the rate of crystallization as well. The
XRD traces of metronidazole and those of the ﬁber mat
containing 12.2 and 25.7 wt% of the drug are presented in
Figure 1. The characteristic reﬂections of metronidazole can
be detected in the traces and their intensity increases with
increasing concentration. Obviously, not the entire amount of
the drug added to the spinning solution is dissolved in the
polymer, but it precipitates during ﬁber spinning and is dis-
persed in crystalline form among and/or inside the ﬁbers. The
location and physical form of metronidazole may inﬂuence
drug release signiﬁcantly, thus determining both the efﬁ-
ciency of the device and its lifetime, the length of the active
period.
The XRD traces of disks containing 25.7 wt% metroni-
dazole are presented in Figure 2 before and after drug release
(dissolution). The intensity of characteristic peaks belonging
to metronidazole decreases during the dissolution experiment
as an effect of drug release. It can also be seen that some
metronidazole remains in the device even after the dissolution
experiment, which conﬁrms our earlier assumption that some
of the drug precipitates during ﬁber spinning and crystals are
located not only among, but also within the ﬁbers. The release
of this latter part of the drug is quite slow and does not take
place in the timescale of the dissolution experiment.
The structure of the ﬁber mat and the disks was also
studied by scanning electron microscopy. Micrographs
showing the differences in structure are presented in
Figure 3. The mat consists of loose ﬁbers with considerable
space among individual ﬁbers (Figure 3A). One would
expect fast penetration and easy ﬂow of the ﬂuid used for
dissolution and thus very fast release of the drug. The
scrutiny of micrographs recorded on mats reveals the pre-
sence of metronidazole crystals among the ﬁbers. The struc-
ture of a disk is shown in the micrograph of Figure 3B. The
disk has a much more compact structure, voids are smaller,
and the ﬁbers are close to each other. The presence of
5 10 15 20 25 30 35
c)
b)
).u.a(
ytisnetnI
Angle of reflection, 2  (°)
12.2 wt% drug
25.7 wt%
a)
Figure 1 Inﬂuence of metronidazole content on the structure of PLA ﬁber mats,
where: a) neat metronidazole, b) 12.2 wt%, and c) 25.7 wt% drug.
5 10 15 20 25 30 35
).u.a(
ytisnetnI
Angle of reflection, 2  (°)
a)
b)
Figure 2 Effect of the dissolution of the drug on the structure of disks prepared
from electrospun ﬁbers by compression. Metronidazole content: 25.7 wt%. a)
before and b) after the dissolution experiment.
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metronidazole crystals among the ﬁbers is more obvious in
this case. The SEM study veriﬁed the conclusions drawn
from the XRD measurements and proves that a part of the
drug is distributed in crystal form among and probably also
within the ﬁbers.
Penetration of the Aqueous Medium,
Wetting
In order to obtain some idea about the penetration of the
dissolution medium into the devices prepared, the contact
angle of water was measured on them as a function of time.
The results are presented in Table 1. Interpretation is difﬁcult
because of the complexity of the system and the related
processes. Contact angle is usually measured by placing
a droplet of a liquid onto a smooth, stable surface. In our
case, the surface used for the measurement is neither stable
nor smooth. Metronidazole dissolves in water, while both
the ﬁber mats and the compressed disks have rough, porous
surfaces (see Figure 3) into which the liquid may penetrate.
Accordingly, the contact angle measured depends on the rate
of dissolution in the case of metronidazole, and on surface
tension and surface morphology in the case of the two
devices. Pore size and capillary forces also play an important
role in the determination of the value of the contact angle,
but also in drug release. Since the surface tension of the
components is constant and we do not expect large changes
in the surface tension of PLA as an effect of the dissolution
of some metronidazole, the major factors must be morphol-
ogy, porosity, and capillary forces.
According to the results of Table 1, the contact angle of
water on the metronidazole pastille is small, which is not
very surprising since metronidazole dissolves in water.
Dissolution is conﬁrmed by the fact that the contact
angle could not be measured after 10 mins of forming
the droplet. Contrary to metronidazole, the contact angle
of the droplet placed onto the ﬁber mat is quite large,
indicating poor wetting and penetration. Contact angle
does not change with metronidazole content; the differ-
ences are caused by changes in morphology and the stan-
dard deviation of the measurements. Contact angles
showed just a slight systematic decrease with time for
the neat ﬁber mats, indicating that water can slowly pene-
trate into the mat.
The contact angle measured on the compressed disks is
much smaller and it is independent of the concentration of
metronidazole as well. It decreases considerably with time
and could not be measured after 10 mins at all, showing
that the water droplet placed onto the disk disappeared in
this time interval. The difference in the contact angles
measured on the ﬁber mat and the compressed disk proves
A
B
Figure 3 SEM micrographs recorded on the PLA devices studied. A) ﬁber mat, B)
compressed disk. The black dots are crystalline metronidazole particles in Figure 3B.
Table 1 Contact Angles Measured (Mean and SD Values) on
a Metronidazole Pastille and on Drug Release Devices (Fiber
Mats, Disks) at Various Times
Device Drug
Content
(wt%)
Contact Angle (°) After Time (Min)
0 10 20
MZ pastille 100 32.5 ± 1.8 – –
Fiber mat 0 125.3 ± 3.8 123.2 ± 4.0 121.4 ± 0.8
12.2 110.8 ± 3.1 104.6 ± 5.3 96.0 ± 8.9
25.7 117.3 ± 7.2 112.3 ± 9.5 105.8 ± 12.2
Disk 0 62.5 ± 1.6 48.7 ± 0.5 –
12.2 66.9 ± 1.4 46.4 ± 0.3 –
25.7 64.3 ± 0.5 47.0 ± 0.2 –
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that the primary factor determining aqueous media pene-
tration is morphology and this factor is expected to deter-
mine the extent and rate of drug release as well.
The apparent contradiction that water cannot penetrate
so fast into the loose ﬁber mats, while it does into the
discs, should be considered. Capillary forces depend on
the interaction of the liquid and the capillary and also on
the size of the capillary, i.e., on pore size, in our case.
Water climbs in a glass capillary, but the level of mercury
decreases in it. The surface tension of water is 72 mJ/m2,
while that of mercury is 486 mJ/m2; thus, the ﬁrst wets
glass, while the other does not. In our case, the surface
tension of water is still the same (72 mJ/m2) as mentioned
above and that of PLA is around 40 mJ/m2.27–29
Accordingly, water does not wet PLA ﬁbers and cannot
penetrate into the devices easily. Compression obviously
changed the pore structure of the device (see Figure 3),
which decreases capillary forces and helps penetration. As
an effect of changing morphology and penetration, we may
expect a faster release of the drug from the disk than from
the ﬁber mat.
In vitro Drug Release
The release of the drug incorporated into the devices
prepared from electrospun ﬁbers is a complex process
and depends on several factors. As the results of the
XRD measurements (Figures 1 and 2) and the SEM micro-
graphs (Figure 3) showed the drug, metronidazole in this
case, is incorporated into the devices in various forms: as
precipitated crystals within and among the ﬁbers and as
dissolved molecules in PLA. The dissolution of these
forms must be different. The PBS solution must penetrate
the device, dissolve the crystals and diffuse out into the
surrounding medium. On the other hand, dissolved metro-
nidazole must diffuse out of the PLA ﬁbers into the sur-
rounding medium. The solubility of metronidazole is small
in PLA, and diffusion is driven by concentration differ-
ence, which is also small or even negative due to the large
drug concentration of the surrounding solution because of
the dissolution of the crystals. Consequently, the main
factor determining the dissolution of metronidazole from
the devices, i.e., drug release, is the penetration and ﬂow
of the PBS solution. This is different for the two devices,
mats and disks; thus dissimilar drug release is expected
from them.
The time dependence of dissolution is presented in
Figure 4 for the ﬁber mats and the disks at two different
concentrations. In view of the observations presented
in Section 3.2, some of the results were expected.
Compressed disks release the drug much faster than ﬁber
mats because of the larger and faster penetration of the
aqueous medium into the pores of the device. However,
the fact that dissolution is independent of the initial con-
centration of metronidazole in the device is somewhat
surprising. The fast penetration and dissolution of metroni-
dazole in the PBS solution can result in the independence of
concentration. The diffusion of the liquid containing the
dissolved drug into the surrounding medium may be the
rate-determining step of dissolution in this case.
In the case of the ﬁber mats, the rate of dissolution
depends on concentration, however, not as expected, i.e.,
faster rate at larger concentration, but in the opposite
way. The slower release of the drug from the mats can
be understood easily if we consider the difference in the
penetration of the aqueous medium (see Table 1). The
effect of concentration, on the other hand, is difﬁcult to
explain. Obviously, the dissolution of the drug in the
PBS solution and its diffusion into the surrounding
medium are the rate-determining steps in this case.
However, the presence of the drug cannot inﬂuence the
diffusion rate much; thus, dissolution must be dissimilar
at the two concentrations of metronidazole. The larger
drug concentration probably results in larger precipitated
crystals, which leads to slower dissolution and release.
0 30 60 90 120 150 180 210
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Figure 4 Dissolution of metronidazole from ﬁber mats and disks. Effect of drug
content. Symbols: (□,■) 12.2 wt%, (○,●) 25.7 wt% metronidazole; empty symbols:
ﬁber mat, full symbol: disk; solid lines are ﬁtted functions, while the broken line
shows the two-step process.
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The rate of dissolution can be estimated qualitatively
from the correlations presented in Figure 4. According to
this evaluation, plateau concentrations are reached after 24
hrs for the disks, and after 48 or 96 hrs for the ﬁber mats.
However, time dependence can be evaluated quantitatively if
appropriate functions are ﬁtted to the experimental data. The
dissolution and the diffusion of the drug are determined by
Fick’s laws. Fick’s equations can be solved numerically or
they can be expressed analytically using simpliﬁcations.30
Two main approaches are used in practice, those describing
the ﬁrst part of the function plotting experimental results as
the function of the square root of time, or those which use an
exponential function. This approach gives a more accurate
estimate at long times and it allows the estimation of the
overall rate of dissolution and the maximum amount of
dissolved material at inﬁnite time (if the shape and structure
of the device do not change, e.g.: ﬁber degradation). We
followed the latter approach and ﬁtted the function of
Equation 1 to the experimental results:
Mt ¼ M1 1 8
π2
exp atð Þ þ 1
9
exp 9atð Þ þ 1
25
exp 25atð Þ
  
(1)
where Mt and M∞ are the dissolved amount of drug at time
t and at inﬁnite time, respectively, and a is the overall rate
of dissolution. The ﬁtted functions are presented in Figure 4
as solid lines. The parameters calculated from the ﬁtting are
collected in Table 2.
Results presented in Table 2 conﬁrm our qualitative
evaluation and show that dissolution is much faster from
the disk than from the ﬁber mat (see parameter a). It also
conﬁrms the composition dependence observed. The com-
parison of the predicted amount of drug dissolved at inﬁ-
nite time (M∞) indicates that a considerable amount of
drug, 10–30% remains in the devices after the dissolution
experiment even in the case of the disks. Moreover,
a closer comparison of the ﬁtted lines and the measured
values indicates that dissolution cannot be described with
a single process; it consists of at least two steps, a faster
one at the beginning of the experiment and another one
proceeding at a slower rate. This two-step process is
demonstrated especially well by the results obtained on
the ﬁber mat containing 25.7 wt% metronidazole (see Δ
series in Figure 4). The two steps demonstrated by the
broken line in the ﬁgure might be explained by the dis-
solution of the different forms of the drug; crystals located
among the ﬁbers dissolve much faster than dissolved
metronidazole or crystals precipitated within the ﬁbers.
In this case, signiﬁcant differences could be observed
(from 2.5 to 6 hrs: p ≤ 0.001; from 6 to 30 hrs: p ≤ 0.01;
and from 30 to 72 hrs: p ≤ 0.05) between the drug release
of ﬁber mats and disks. The different rates allow the
regulation of the amount of the drug as a function of
time and also the active lifetime of the device.
Controlling the form of the drug in the device and the
rate of water diffusion into the electrospun porous ﬁber
network might be an efﬁcient strategy to control drug
release.31,32
Antimicrobial Activity
The oral cavity and/or various dental surfaces may be inhab-
ited by numerous strains of pathogen bacteria. Personal fea-
tures, dietary habits, or even habitation could have an inﬂuence
on the composition of the oral microbiota.33,34 The contribu-
tion of different bacterial strains to the initiation and progres-
sion of periodontitis is under serious investigation.33–41
However, the task seems to be almost impossible because of
the large number of various microorganism species, difﬁcul-
ties of cultivation, and the fact that only a small part of the
bacteria present in the subgingival cavity could be linked to the
pathogenesis of the disease.42 Pathogens playing a role in the
formation and progression of periodontal disease can be sub-
divided into three groups. The ﬁrst category strains are able to
stick to dental surfaces, the bacteria in the second group form
a bridge between the ﬁrst and the third category, while the
bacteria of the third group are responsible for bacterial bioﬁlm
formation (Socransky and Haffajee, 2002). The following
strains may initiate disease formation: Porphyromonas
gingivalis, P. intermedia, Bacteroides forsythus, A. actinom-
ycetemcomitans, Treponema denticola, Tannerella forsythia,
F. nucleatum, Fusobacterium periodonticum, Prevotella
nigrescens, P. micra, Campylobacter gracilis, Campylo-
bacter rectus, Campylobacter showae, Eubacterium nodatum,
Streptococcus constellatus, E. corrodens, Streptococcusspp.,
etc.33,42–44
Only disks were included in the microbiological study, as
uniform shape, weight, and thickness could not have been
Table 2 Parameters Characterizing the Kinetics of Dissolution
Determined by Fitting Equation 1 to the Experimental Results
Drug Content (wt%) Form a (1/hr) M∞ (%) R
2a
12.2 Mat 0.233 81.9 0.8855
25.7 Mat 0.051 71.8 0.9634
12.2 Disk 0.581 89.4 0.9449
25.7 Disk 0.556 89.1 0.9650
Notes: aDetermination coefﬁcient showing the goodness of the ﬁt.
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achieved with the ﬁber mats. The delivery systems evaluated
contained 12.2 and 25.7 wt% metronidazole. Five different
bacterial strains were used in this investigation: E. corrodens,
P. intermedia, P. micra, F. nucleatum, and A. actinomycete-
mcomitans. E. corrodens is a facultative anaerobic, gram-
negative bacterium and a human (mostly oral) pathogen.
E. corrodens is reported to be unsusceptible to metronid-
azole.45 P. micra is a gram-positive, anaerobic coccus and
part of the normal human gastrointestinal ﬂora.46 Literature
data suggest that this strain is not susceptible to metronida-
zole either.47 P. intermedia is a black pigmented, gram-
negative anaerobic bacterium. It is often connected with
oral and subgingival diseases. Metronidazole is efﬁcient
against P. intermedia.48 F. nucleatum, which is a mostly
oral and periodontal anaerobic pathogen bacterium, can be
related to several human diseases. This strain seems to be
sensitive to metronidazole.49,50
A facultatively anaerobic gram-negative bacterium,
A. actinomycetemcomitans, can often be linked to period-
ontal disease and oral infections. Susceptibility to metro-
nidazole is reported to be weak.51,52
The results of the microbiological study are presented
in Figure 5. The duration of the antimicrobial effect is
apparently independent of concentration; it is the same
for disks with 12.2 and 25.7 wt% metronidazole content
in most cases. A one-day difference appeared in growth
inhibition for P. micra at 12.2 and 25.7 wt% metronidazole
contents. In the other cases, disks with a larger metroni-
dazole content provided slightly larger inhibition zones
than systems containing less drug on most days.
Bacterial growth inhibition is shorter, only 2–3 days for
A. actinomycetemcomitans, E. corrodens and P. micra,
while the growth of F. nucleatum and P. intermedia was
affected for a longer time, for 13 days.
The results of our measurements agree well with those
published in the literature, suggesting that F. nucleatum and
P. intermedia are more susceptible to metronidazole than
A. actinomycetemcomitans, E. corrodens and P. micra,
which may be completely resistant or minimally sensitive
to the antimicrobial drug used. The diameter of the inhibi-
tion zone increases slightly with increasing metronidazole
concentration, probably because of longer diffusion paths
resulting in enhanced inhibition. The differences in the
diameter of the inhibition zone are more pronounced for
strains with larger susceptibility to metronidazole and they
increase with time as well. Inhibition was observed in the
growth of susceptible bacteria for as long as almost 2
weeks, indicating that our devices can be efﬁcient for
a long time. This fact, however, needs some consideration,
since the dissolution study indicated that most of the drug is
released from the disks in 24 hrs. The contradiction might
be explained by the difference in the conditions, but also in
the presence of metronidazole located within the polymer in
the form of dissolved molecules or precipitated crystals.
The diffusion, thus the release rate of metronidazole is
much slower in this latter case than for the drug located
among the ﬁbers in crystal form. A slower rate leads to
prolonged inhibition times, which could result in greater
patient compliance and better results of the periodontitis
treatment.
Conclusion
The XRD study of drug release devices prepared from
electrospun PLA ﬁbers showed that the polymer was par-
tially crystalline in both devices, i.e., in ﬁber mats and
disks. A part of metronidazole precipitated and was located
in the form of crystals among the ﬁbers. The penetration of
the aqueous medium and dissolution were different in the
two devices, they were faster in disks and slower in ﬁber
mats, due to the morphology of the device and because of
the action of capillary forces. Disks released the drug much
faster than ﬁber mats. The microbiological study carried out
with ﬁve bacterial strains conﬁrmed results published in the
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Figure 5 Inhibition zones (mean and SD values) developing in the presence of
different anaerobic pathogen bacteria of the oral cavity using disks, which contain
various amounts of metronidazole. Symbols: (○) P. intermedia, (□) F. nucleatum, (Δ)
A. actinomycetemcomitans, (∇) P. micra, (◊) E. corrodens; empty symbol: 12.2 wt%, full
symbol: 25.7 wt% metronidazole.
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open literature that some strains are insensitive to metroni-
dazole (A. actinomycetemcomitans, E. corrodens, P. micra),
while the drug is very efﬁcient against others (F. nucleatum,
P. intermedia). Although the release study indicated the fast
dissolution of the drug, the concentration achieved a plateau
value in 24 hrs for the disks; the inhibition effect was much
longer, 13 days for bacteria sensitive to metronidazole. The
longer inhibition period could be explained by the slower
diffusion of metronidazole located inside the ﬁbers of the
devices and the slow penetration of the aqueous medium
into them. The results indicated that in all probability the
devices prepared may be effective in the treatment of
periodontitis.
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